Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 134523-00-5] Atorvastatin
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B0589 |
| Brand: | MCE |
| CAS: | 134523-00-5 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 558.64 |
| Molecular Formula | C33H35FN2O5 |
| SMILES | O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4 |
For research use only. We do not sell to patients.
27 Publications Citing Use of MCE
- [1]Signal Transduct Target Ther. 2023 Dec 25;8(1):457.
- [2]Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.
- [3]Cancer Lett. 2022 Oct 19;215976.
- [4]Cell Death Dis. 2021 May 13;12(5):482.
- [5]Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658.
- [6]Oncogene. 2022 Oct 31.
- [7]Phytomedicine. 2023 Jul 26;119:154997.
- [8]Biomed Pharmacother. 2023 Aug 12;166:115323.
- [9]Front Bioeng Biotechnol. 2022 Mar 17;10:826093.
- [10]Int J Mol Sci. 2023 Apr 19, 24(8), 7492.
- [11]Front Cell Dev Biol. 2022 Mar 3;10:806081.
- [12]Pharmaceutics. 2022, 14(1), 176.
- [13]J Nat Prod. 2022 Jun 24.
- [14]Eur J Pharmacol. 2023 Dec 21:176261.
- [15]Eur J Pharmacol. 2023 Aug 1;956:175938.
- [16]Endocrinology. 2022 May 18;bqac076.
- [17]Endocrinology. 2018 May 1;159(5):2008-2021.
- [18]Sci Rep. 2020 Jan 28;10(1):1308.
- [19]Cell Cycle. 2021 Sep 8;1-14.
- [20]Cell Cycle. 2019 Dec;18(23):3337-3350.
- [21]Biotechnol Bioeng. 2021 Sep 3.
- [22]Exp Cell Res. 2023 Oct 23:113829.
- [23]Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun 8.
- [24]Proteomics. 2023 May 4;e2300041.
- [25]J Neuroimmunol. 2020 Oct 24;350:577429.
- [26]J Mol Neurosci. 2021 Sep 26.
- [27]Research Square Preprint. 2021 Dec.
Summary
In Vitro
Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation [4] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE −/− mice) treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/- mice. Proinflammatory cytokines such as IL-6 , IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment [5] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Forty 8-week-old ApoE −/− mice induced with angiotensin II (Ang II) [5] |
| Dosage: | 20 mg/kg, 30 mg/kg |
| Administration: | Oral gavage; once a day; for 28 days |
| Result: | Significantly reduced ER stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE −/− mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β were all remarkably inhibited. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00124397 | University of Southern Denmark|Pfizer |
Type 2 Diabetes Mellitus
|
July 2001 | Phase 4 |
| NCT00329173 | AstraZeneca |
Hypercholesterolaemia
|
November 2003 | Phase 3 |
| NCT03692754 | Shandong University |
Immune Thrombocytopenia|Purpura, Thrombocytopenic
|
November 1, 2021 | Phase 2|Phase 3 |
| NCT00432354 | Buddhist Tzu Chi General Hospital|Pfizer |
Systemic Lupus Erythematosus
|
March 2007 | Phase 2|Phase 3 |
| NCT03186404 | University Health Network, Toronto|Mount Sinai Hospital, Canada|Unity Health Toronto|Sunnybrook Health Sciences Centre|Scarborough General Hospital |
Cancer|Heart Failure|Cardiotoxicity
|
May 10, 2018 | Phase 2 |
| NCT03760848 | Galmed Pharmaceuticals Ltd|Hammersmith Medicines Research|Analyst Research Laboratories|Alderley Analytical|Diamond Pharma Services Regulatory Affairs Consultancy |
Healthy
|
November 12, 2018 | Phase 1 |
| NCT05705804 | Yonsei University |
Dyslipidemias|Atherosclerotic Cardiovascular Disease
|
June 13, 2023 | Not Applicable |
| NCT00194402 | University of Washington|Upsher-Smith Laboratories |
Dyslipidemia
|
August 2003 | Phase 4 |
| NCT03820466 | Dr. med. Mahir Karakas|Universitätsklinikum Hamburg-Eppendorf |
Acute Chest Syndrome
|
February 21, 2020 | Phase 3 |
| NCT03745300 | Government Dental College and Research Institute, Bangalore |
Chronic Periodontitis Wth Diabetes Mellitus
|
March 3, 2017 | Phase 2|Phase 3 |
| NCT01964326 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypercholesterolemia
|
October 2013 | Phase 3 |
| NCT02286544 | Karolinska Institutet|University Hospital, Linkoeping |
Myocardial Infarction|Inflammation|Acute Coronary Syndrome (ACS)|Reperfusion Injury
|
October 2014 | Phase 1 |
| NCT00782184 | Organon and Co |
Hypercholesterolemia
|
November 2008 | Phase 3 |
| NCT00559962 | Aegerion Pharmaceuticals, Inc. |
Hyperlipidemia
|
October 2007 | Phase 2 |
| NCT00701220 | Philip Binkley|Pfizer|Ohio State University |
Cardiovascular Disease|Cardiomyopathy|Heart Disease|Myocardial Disease|Myocardial Ischemia
|
April 2007 | Phase 4 |
| NCT03433196 | Zhejiang Hisun Pharmaceutical Co. Ltd. |
Hypercholesterolemia in Coronaory Heart Disease
|
June 7, 2016 | Phase 3 |
| NCT02967653 | Lady Davis Institute |
Lithium Use, Nephrogenic Diabetes Insipidus
|
July 13, 2017 | Phase 2 |
| NCT01138072 | GlaxoSmithKline |
Infection, Human Immunodeficiency Virus
|
June 2010 | Phase 1 |
| NCT01765023 | HK inno.N Corporation |
Healthy
|
October 2012 | Phase 1 |
| NCT00647543 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Dyslipidemias
|
August 2003 | Phase 4 |
| NCT01299597 | GlaxoSmithKline |
Sleep Disorders
|
January 18, 2010 | Phase 1 |
| NCT05251129 | Montefiore Medical Center |
Vasculopathy
|
January 2024 | Not Applicable |
| NCT00343655 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Cardiovascular Diseases
|
January 2007 | Phase 3 |
| NCT02740699 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Cardiovascular Disease
|
April 11, 2016 | Phase 4 |
| NCT00004564 | National Center for Research Resources (NCRR) |
Hypercholesterolemia|Thrombosis
|
Not Applicable | |
| NCT00239330 | AstraZeneca |
Hypercholesteremia
|
June 2003 | Phase 3 |
| NCT05895123 | Damanhour University|Alexandria University |
ST-segment Elevation Myocardial Infarction
|
October 1, 2022 | Phase 2 |
| NCT01518231 | Zhejiang Hospital|Zhejiang University |
Stroke
|
January 2012 | Phase 1 |
| NCT00344019 | Beth Israel Deaconess Medical Center|Pfizer |
Coronary Disease
|
May 2006 | Phase 4 |
| NCT00368589 | GlaxoSmithKline |
Atherosclerotic Carotid Disease|Atheroma|Atherosclerosis
|
July 2006 | |
| NCT05342974 | University of Utah|Grand Challenges Canada |
Abortion Early
|
April 19, 2022 | Early Phase 1 |
| NCT05870007 | Taipei Medical University Shuang Ho Hospital|University of Southern California |
Autosomal Dominant Polycystic Kidney Disease|Chronic Kidney Diseases
|
May 2023 | Phase 2 |
| NCT01126684 | Aristotle University Of Thessaloniki |
Hypertension|Hypercholesterolemia
|
June 2008 | Not Applicable |
| NCT00094172 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Multiple Sclerosis
|
May 2005 | Phase 2 |
| NCT00115817 | Brigham and Women´s Hospital |
Atherosclerosis
|
June 2005 | Phase 3 |
| NCT04945122 | Chinese Academy of Medical Sciences, Fuwai Hospital |
Acute Myocardial Infarction|Glucose Metabolism Disorders
|
October 1, 2015 | Phase 4 |
| NCT01185236 | Seoul National University Hospital|Merck Sharp & Dohme LLC |
Type 2 Diabetes Mellitus Without Insulin Treatment
|
September 2010 | Phase 4 |
| NCT00150722 | University of Calgary|Heart and Stroke Foundation of Ontario |
Atherosclerosis
|
September 2005 | Phase 3 |
| NCT00017758 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections|HIV Seronegativity|Lipodystrophy
|
Phase 1 | |
| NCT00701883 | CymaBay Therapeutics, Inc. |
Hyperlipidemia
|
August 2007 | Phase 2 |
| NCT02943590 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women´s Hospital |
Heart Failure
|
January 13, 2017 | Phase 2 |
| NCT04380402 | Mount Auburn Hospital |
COVID-19
|
June 25, 2020 | Phase 2 |
| NCT00065806 | Laura Schanberg|Duke University |
Lupus Erythematosus, Systemic
|
September 2003 | Phase 3 |
| NCT02156492 | Eli Lilly and Company |
Healthy Volunteers
|
June 2014 | Phase 1 |
| NCT02260648 | Eli Lilly and Company |
Hypercholesterolemia
|
January 2015 | Phase 3 |
| NCT02114346 | Isfahan University of Medical Sciences |
Contrast-Induced Nephropathy
|
July 2013 | Phase 2|Phase 3 |
| NCT03882996 | Organon and Co |
Hypercholesterolemia
|
October 6, 2000 | Phase 3 |
| NCT05483010 | Washington University School of Medicine |
Clonal Cytopenia of Undetermined Significance|Myelodysplastic Syndromes
|
June 30, 2023 | Phase 2 |
| NCT02522117 | Instituto Mexicano del Seguro Social |
Renal Insufficiency
|
August 2015 | Phase 3 |
| NCT00993915 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Cardiovascular Diseases|Coronary Artery Disease
|
April 2010 | |
| NCT04747847 | University of California, San Diego|National Heart, Lung, and Blood Institute (NHLBI) |
Kawasaki Disease
|
October 9, 2017 | Early Phase 1 |
| NCT01768481 | Université de Montréal|Pfizer |
Obesity|Dyslipidemia
|
January 2004 | Phase 3 |
| NCT02679261 | Hospital Universitari Vall d´Hebron Research Institute |
Bicuspid Aortic Valve
|
June 2016 | Phase 3 |
| NCT00767572 | University of California, San Francisco|American Heart Association |
Coarctation of the Aorta
|
August 2008 | Phase 4 |
| NCT01617772 | Tehran University of Medical Sciences |
Non-alcoholic Steatohepatitis
|
January 1, 2016 | Phase 2 |
| NCT02984982 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolemia|Acute Coronary Syndrome
|
November 15, 2016 | Phase 4 |
| NCT03355027 | Cambridge University Hospitals NHS Foundation Trust|University of Cambridge |
Atherosclerosis|Cardiovascular Diseases
|
November 30, 2017 | Not Applicable |
| NCT00181181 | Johns Hopkins University|American Heart Association|Procris Pharmaceuticals |
Hypertension
|
May 2003 | Phase 4 |
| NCT05583643 | Misr University for Science and Technology |
Periodontitis
|
December 7, 2021 | Phase 1 |
| NCT01072097 | University of Oulu|Pfizer |
Polycystic Ovary Syndrome
|
September 2006 | Not Applicable |
| NCT00185731 | Dean Felsher|The Leukemia and Lymphoma Society|Damon Runyon Cancer Research Foundation|Burroughs Wellcome|Stanford University |
Leukemia|Lymphoma, Non-Hodgkin
|
April 2005 | Phase 2 |
| NCT00519363 | The Center for Rheumatic Disease, Allergy, & Immunology|Saint Luke´s Health System |
Systemic Lupus Erythematosus
|
September 2007 | Phase 1|Phase 2 |
| NCT04333407 | Imperial College London |
COVID-19
|
April 3, 2020 | Not Applicable |
| NCT01071993 | University of Oklahoma |
Nephropathy
|
March 2010 | Not Applicable |
| NCT00663234 | International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
HIV Infections|Hyperlipidemia
|
August 2009 | Phase 1|Phase 2 |
| NCT05563389 | Tanta University |
Quality of Life
|
June 15, 2022 | Phase 2|Phase 3 |
| NCT01795937 | Boehringer Ingelheim |
Healthy
|
February 2013 | Phase 1 |
| NCT01635946 | Astellas Pharma Global Development, Inc.|Basilea Pharmaceutica International Ltd|Astellas Pharma Inc |
Pharmacokinetics of Isavuconazole|Pharmacokinetics of Atorvastatin|Healthy Volunteers
|
August 2012 | Phase 1 |
| NCT01447797 | Hanmi Pharmaceutical Company Limited |
Healthy
|
September 2011 | Phase 1 |
| NCT01600170 | University of Pennsylvania |
HIV Dementia
|
January 2013 | Phase 4 |
| NCT01748279 | Medical University of Bialystok |
COPD
|
December 2012 | Phase 4 |
| NCT02029118 | Chengdu University of Traditional Chinese Medicine |
Stable Angina Pectoris
|
October 2012 | Early Phase 1 |
| NCT03460808 | Peking University People´s Hospital |
Immune Thrombocytopenia
|
March 10, 2018 | Phase 1|Phase 2 |
| NCT02518503 | Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR) |
Diabetes Mellitus, Type 2|Cardiovascular Disease
|
July 2012 | |
| NCT00716846 | Hamamatsu University |
Healthy Volunteers
|
June 2006 | Not Applicable |
| NCT00276484 | Organon and Co |
Hypercholesterolemia
|
February 2006 | Phase 3 |
| NCT01220973 | Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI) |
Prostate Cancer
|
February 2009 | Phase 2 |
| NCT02566187 | Boryung Pharmaceutical Co., Ltd |
Hypertension|Hyperlipidemia
|
August 2015 | Phase 1 |
| NCT00487994 | Takeda |
Dyslipidemia
|
November 2004 | Phase 3 |
| NCT00259662 | Yale University|Washington Mutual Foundation |
Gynecologic Oncological Pelvic+Abdominal Surgery
|
November 2005 | Not Applicable |
| NCT02157337 | Yonsei University |
Aortic Surgery|Acute Kidney Injury
|
March 12, 2014 | Phase 4 |
| NCT01154036 | Organon and Co |
Hypercholesterolemia
|
July 2010 | Phase 3 |
| NCT00276458 | Organon and Co |
Hypercholesterolemia
|
February 2006 | Phase 3 |
| NCT01442987 | Hanmi Pharmaceutical Company Limited |
Hypertension|Hyperlipidemia
|
May 2011 | Phase 3 |
| NCT02659397 | Esperion Therapeutics, Inc. |
Hyperlipidemia
|
December 2015 | Phase 2 |
| NCT01236365 | Nemours Children´s Clinic|Pfizer|Medtronic|Quest Diagnostics-Nichols Insitute |
Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia
|
October 2010 | Phase 3 |
| NCT01720719 | Xin Gao|Pfizer|Fudan University |
Fatty Liver|Dyslipidemias|Diabetes Mellitus
|
May 2013 | Phase 4 |
| NCT05551624 | Hospital Civil de Guadalajara |
Primary Immune Thrombocytopenia
|
July 4, 2018 | Early Phase 1 |
| NCT01665235 | RenJi Hospital |
Blood Pressure Variability|Intracranial Artery Stenosis
|
August 2012 | Not Applicable |
| NCT02084069 | Urmia University of Medical Sciences |
Heart Valve Diseases
|
January 2013 | Phase 3 |
| NCT02125682 | Hotel Dieu de France Hospital|Nouvelle Société Française d´Athérosclérose|Pfizer |
Dyslipidemia in Patients With Diabetes Mellitus
|
January 2012 | Phase 4 |
| NCT04631536 | Lebanese American University Medical Center |
Covid19
|
January 10, 2021 | Phase 3 |
| NCT00653588 | AstraZeneca |
Hypercholesterolemia|Coronary Heart Disease
|
April 2003 | Phase 3 |
| NCT00292201 | Queen´s University|The Physicians´ Services Incorporated Foundation|Ontario Lung Association |
Asthma
|
February 2006 | Phase 2 |
| NCT01236430 | Organon and Co |
Hyperlipidemia
|
February 2011 | Phase 1 |
| NCT01980823 | Columbia University |
Breast Cancer|Breast Tumors|Cancer of Breast
|
October 2013 | Early Phase 1 |
| NCT01062802 | University of Hull |
Abdominal Aortic Aneurysm
|
January 2005 | Phase 4 |
| NCT01541943 | HanAll BioPharma Co., Ltd. |
Essential Hypertension|Hyperlipidemia
|
March 2012 | Phase 3 |
| NCT00344955 | Regional Hospital Holstebro |
Healthy
|
January 2003 | Phase 4 |
| NCT03830164 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Male Erectile Disorder|Prostate Adenocarcinoma|Erectile Dysfunction, CTCAE|Impotence
|
November 20, 2019 | Phase 2 |
| NCT02023892 | Sun Yat-sen University |
Endothelium|Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
June 2014 | Phase 4 |
| NCT00932048 | Korea University |
Type 2 Diabetes|Atherosclerosis
|
August 2011 | Not Applicable |
| NCT00136981 | Pfizer |
Hypercholesterolemia, Familial|Hyperlipidemia
|
December 2003 | Phase 3 |
| NCT04679376 | Mayo Clinic |
NASH - Nonalcoholic Steatohepatitis
|
January 25, 2023 | Phase 2 |
| NCT00611143 | Samsung Medical Center |
Coronary Artery Bypass
|
May 2006 | Not Applicable |
| NCT01543555 | Hospital do Coracao |
Myocardial Infarction|Peripheral Vascular Disease|Aortic Aneurism
|
November 2012 | Phase 3 |
| NCT02380625 | Clinical Research Management, Inc.|Bill and Melinda Gates Foundation|Duke University|University of Sierra Leone|Syneos Health|University of North Carolina |
Ebola Virus Disease
|
April 2015 | Phase 1|Phase 2 |
| NCT00490698 | M.D. Anderson Cancer Center|Novartis Pharmaceuticals |
Kidney Cancer|Renal Cell Carcinoma
|
October 2006 | Phase 2 |
| NCT02114099 | National Taiwan University Hospital|National Science Council, Taiwan |
Kawasaki Disease|Aneurysm, Coronary
|
June 2007 | Phase 2 |
| NCT01780740 | University of Oxford |
Disorder; Heart, Functional, Postoperative, Cardiac Surgery|Cardiac Insufficiency Following Cardiac Surgery|Atrial Fibrillation|Ischaemia-reperfusion Injury
|
January 2012 | Phase 4 |
| NCT00141232 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Churchill Hospital|Pfizer |
Diabetes, Type 2
|
November 2004 | Phase 4 |
| NCT00327418 | Pfizer|Diabetes UK|Department of Health, United Kingdom |
Major Coronary Event|Cerebrovascular Accident|Coronary Artery Bypass Graft|Angina, Unstable|Revascularization
|
January 1997 | Phase 4 |
| NCT00715273 | University of Washington|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer|Abbott|Daiichi Sankyo, Inc.|Upsher-Smith Laboratories |
Coronary Artery Disease|Carotid Artery Diseases|Atherosclerosis
|
May 1, 2001 | Phase 4 |
| NCT04245046 | Midas Pharma GmbH |
Healthy Volunteers
|
January 18, 2019 | Phase 1 |
| NCT00214630 | AstraZeneca |
Acute Coronary Syndromes
|
December 2003 | Phase 3 |
| NCT00811330 | University Hospital, Strasbourg, France |
Aortic Valve Stenosis|Ventricular Hypertrophy
|
December 2008 | Phase 3 |
| NCT00570752 | Bristol-Myers Squibb |
Vascular Diseases
|
December 2008 | Phase 2 |
| NCT02776956 | xieruiqin|The Second Hospital of Hebei Medical University |
Atrial Fibrillation
|
April 2016 | Not Applicable |
| NCT01988571 | Wake Forest University Health Sciences|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Breast Cancer|Lymphoma
|
February 1, 2014 | Phase 2 |
| NCT00736463 | Oregon Health and Science University|Merck Sharp & Dohme LLC|Oregon State University|Indiana University |
HDL Cholesterol
|
January 2005 | Phase 4 |
| NCT00079638 | Kos Pharmaceuticals |
Dyslipidemia|Coronary Heart Disease|Atherosclerosis|Stroke|Diabetes
|
April 2004 | Phase 4 |
| NCT00967252 | Ottawa Hospital Research Institute |
Inflammation|Infection|Endothelial Function
|
November 2008 | |
| NCT03660293 | Tanta University |
Diabetes Mellitus, Type 1
|
April 1, 2017 | Not Applicable |
| NCT01187992 | San Filippo Neri General Hospital|Associazione Nazionale Medici Cardiologi Ospedalieri |
Acute Coronary Syndrome|Coronary Artery Disease
|
September 2003 | Phase 3 |
| NCT00465088 | Abbott |
Hyperlipidemia|Mixed Dyslipidemia
|
April 2007 | Phase 3 |
| NCT02080455 | Aegerion Pharmaceuticals, Inc. |
Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
|
January 27, 2014 | Phase 1 |
| NCT01043380 | Kumamoto University |
Hypercholesterolemia|Coronary Artery Disease
|
January 2010 | Phase 4 |
| NCT00143676 | Takeda |
Hypercholesterolemia
|
August 2005 | Phase 3 |
| NCT02681653 | Sanjay Gandhi Postgraduate Institute of Medical Sciences |
Septic Shock
|
January 2012 | Not Applicable |
| NCT02901379 | National Cardiovascular Center Harapan Kita Hospital Indonesia |
Myocardial Edema
|
October 2016 | Phase 3 |
| NCT00640744 | Baylor College of Medicine|Pfizer |
Atherosclerosis
|
February 2006 | Phase 4 |
| NCT04453735 | Vestre Viken Hospital Trust|The Hospital of Vestfold|Oslo University Hospital |
Statin Adverse Reaction
|
August 19, 2020 | Phase 4 |
| NCT00535405 | Organon and Co|Merck Shering-Plough JV Study |
Hypercholesterolemia
|
November 2007 | Phase 3 |
| NCT00137462 | Pfizer |
Hyperlipidemia
|
November 2004 | Phase 3 |
| NCT01040936 | Shanghai Jiao Tong University School of Medicine |
Acute Coronary Syndrome
|
May 2010 | Phase 4 |
| NCT01922687 | Shanghai Institute of Hypertension |
Arterial and Arteriolar Disorders
|
April 2011 | Phase 4 |
| NCT00645424 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hyperlipidemias
|
December 2003 | Phase 4 |
| NCT05076019 | Odense University Hospital|Odense Patient Data Explorative Network|GCP-unit at Odense University Hospital |
Postoperative Atrial Fibrillation
|
February 1, 2022 | Not Applicable |
| NCT01115985 | Astellas Pharma Inc |
Healthy|Pharmacokinetics of Atorvastatin
|
March 2010 | Phase 1 |
| NCT00462748 | Organon and Co |
Hypercholesterolemia
|
March 2007 | Phase 3 |
| NCT02113540 | Isfahan University of Medical Sciences |
Contrast Induced Nephropathy
|
January 2012 | Phase 3 |
| NCT02749578 | Madrigal Pharmaceuticals, Inc.|Celerion |
Healthy
|
April 2016 | Phase 1 |
| NCT00620542 | AstraZeneca|The Cleveland Clinic |
Coronary Atherosclerosis
|
January 2008 | Phase 3 |
| NCT00722956 | AstraZeneca |
Healthy Volunteers|Pharmacokinetics
|
July 2008 | Phase 1 |
| NCT02245269 | Boehringer Ingelheim |
Healthy
|
July 2003 | Phase 1 |
| NCT00795912 | St Vincent´s University Hospital, Ireland|University of Dublin, Trinity College|University College Dublin|University College Cork |
Heart Failure
|
May 2003 | Phase 4 |
| NCT03228017 | NYU Langone Health |
Cardiovascular Diseases|Myocardial Infarction|Atherosclerotic Cardiovascular Disease|Thrombotic Vascular Disease
|
August 1, 2017 | Phase 4 |
| NCT00791648 | Vanderbilt University Medical Center |
Acute Kidney Injury|Post-Operative Delirium|Icu Delirium|Acute Renal Failure|Delirium
|
July 2009 | Not Applicable |
| NCT01293097 | Peking University First Hospital |
Non-ST Segment Elevation Myocardial Infarction|Unstable Angina Pectoris|Stable Angina Pectoris
|
June 2010 | Phase 4 |
| NCT00446940 | Bader, Ted, M.D. |
Hepatitis C
|
December 2006 | Phase 2 |
| NCT00861861 | Kumamoto University |
Hypercholesterolemia|Coronary Artery Disease
|
September 2008 | Phase 4 |
| NCT04685642 | Taipei Veterans General Hospital, Taiwan |
Mood Disorder
|
August 24, 2020 | Phase 4 |
| NCT03037372 | Makerere University|University of Oxford|Case Western Reserve University |
HIV Infection
|
June 1, 2017 | Phase 3 |
| NCT02135029 | Pfizer |
Hyperlipidemia
|
June 2014 | Phase 3 |
| NCT00457340 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Arrhythmia
|
February 2000 | Phase 4 |
| NCT02984293 | University of Dundee|NHS Tayside |
Drug Intolerance
|
April 17, 2017 | Phase 4 |
| NCT00678522 | Regional Hospital Holstebro|Medical Research |
Healthy Subjects
|
September 2007 | Phase 4 |
| NCT05028829 | Raymond Chung|University of Texas Southwestern Medical Center|Massachusetts General Hospital |
Liver Fibroses|Cirrhosis
|
May 10, 2023 | Phase 2 |
| NCT01730040 | Regeneron Pharmaceuticals|Sanofi |
Hypercholesterolemia
|
October 2012 | Phase 3 |
| NCT05049603 | University of Pisa|Università degli Studi dell´Insubria|University of Catania|University of Messina |
Graves´ Orbitopathy
|
January 1, 2024 | Phase 3 |
| NCT00133380 | Eli Lilly and Company |
Hypercholesterolemia
|
July 2005 | Phase 2 |
| NCT00134264 | Pfizer |
Coronary Disease|Diabetes Mellitus
|
July 2004 | Phase 3 |
| NCT01086020 | Shanghai Jiao Tong University School of Medicine |
Coronary Artery Disease
|
January 2010 | Phase 4 |
| NCT03769870 | Handok Inc. |
Diabete Mellitus
|
January 11, 2019 | Phase 1 |
| NCT00345202 | Regional Hospital Holstebro |
Healthy
|
September 2004 | Phase 4 |
| NCT00491530 | Abbott |
Mixed Dyslipidemia
|
June 2007 | Phase 3 |
| NCT02060032 | Government Dental College and Research Institute, Bangalore |
Chronic Periodontitis
|
February 2013 | Phase 2|Phase 3 |
| NCT00741715 | Sanofi |
Hypercholesterolemia
|
August 2008 | Phase 3 |
| NCT04721795 | Obafemi Awolowo University Teaching Hospital|University Hospital Birmingham NHS Foundation Trust|Cures Within Reach |
Tuberculosis, Pulmonary|Tuberculosis
|
January 19, 2021 | Phase 2|Phase 3 |
| NCT03289429 | Assiut University |
Arrhythmias
|
September 24, 2017 | Phase 4 |
| NCT02030054 | University of Roma La Sapienza |
Coronary Artery Disease
|
January 2015 | Phase 4 |
| NCT00362934 | Solvay Pharmaceuticals |
Hyperlipidemia
|
October 2006 | Phase 3 |
| NCT04718155 | Assiut University |
Traumatic Brain Injury
|
March 1, 2021 | Not Applicable |
| NCT01837069 | NYU Langone Health |
Osteoarthritis|Cardiovascular Disease
|
February 2014 | Phase 4 |
| NCT04900155 | Penza State University |
STEMI|Covid19|NSTEMI
|
November 20, 2020 | Not Applicable |
| NCT00914017 | University of Vermont|Breast Cancer Research Foundation|Cancer and Leukemia Group B |
Breast Cancer
|
January 2005 | Phase 2 |
| NCT01351025 | AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Pfizer |
HIV-1 Infection
|
April 14, 2011 | Phase 2 |
| NCT01779687 | Radboud University Medical Center|Merck Sharp & Dohme LLC |
HIV|Hypercholesterolaemia
|
March 2013 | Phase 1 |
| NCT03768427 | Organon and Co |
Hypercholesterolemia
|
May 27, 2019 | Phase 3 |
| NCT00540293 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Dyslipidemias
|
October 2007 | Phase 4 |
| NCT05912686 | Zhongda Hospital |
Mechanical Thrombectomy|Acute Ischemic Stroke
|
July 1, 2023 | Phase 4 |
| NCT01341730 | The Catholic University of Korea|Jeil Pharmaceutical Co., Ltd. |
Atherosclerosis|Coronary Artery Disease
|
June 2011 | Phase 4 |
| NCT01375075 | Eli Lilly and Company |
Dyslipidemias
|
June 2011 | Phase 2 |
| NCT01821404 | Tampere University Hospital|Tampere University|Fimlab laboratories|University of Eastern Finland|Finnish Cultural Foundation |
Prostatic Neoplasms
|
August 2012 | Phase 2 |
| NCT02432534 | Centre Hospitalier Universitaire de Nice |
Vitiligo
|
May 2015 | Phase 2 |
| NCT00442845 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Coronary Arteriosclerosis|Diabetes Mellitus, Type 2|Cerebrovascular Accident|Dyslipidemia|Peripheral Vascular Disease
|
January 2003 | Phase 4 |
| NCT04789057 | Medical University of Bialystok|Medical Research Agency, Poland |
Copd|COPD Exacerbation|Smoking|Gene Expression|Atorvastatin
|
February 11, 2022 | Phase 4 |
| NCT03510715 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolemia
|
August 31, 2018 | Phase 3 |
| NCT00609063 | Hartford Hospital|National Heart, Lung, and Blood Institute (NHLBI) |
Hydroxymethylglutaryl-CoA Reductase Inhibitors|Muscular Diseases
|
January 2008 | Not Applicable |
| NCT00199745 | Oslo University Hospital|University of Oslo School of Pharmacy |
Muscular Diseases
|
October 2005 | Phase 4 |
| NCT00505336 | St Vincent´s University Hospital, Ireland |
Diastolic Heart Failure
|
April 2006 | Not Applicable |
| NCT01175148 | West Virginia University |
Graft vs Host Disease
|
July 2010 | Phase 2 |
| NCT00004466 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Southwest Pediatric Nephrology Study Group |
Nephrotic Syndrome|Hyperlipidemia
|
October 1998 | Phase 2 |
| NCT04347434 | Penza State University |
Myocardial Infarction, Acute|Myocardial Strain|Arterial Stiffness|Quality of Life
|
February 12, 2020 | Phase 4 |
| NCT05681273 | Chipscreen Biosciences, Ltd. |
T2DM
|
February 17, 2023 | Phase 1 |
| NCT00463827 | NHS Greater Clyde and Glasgow|University of Glasgow|Medical Research Council |
Asthma|COPD|Smoking
|
August 2007 | Phase 2 |
| NCT01208701 | Erling Bjerregaard Pedersen|Regional Hospital Holstebro |
Nephropathy|Cardiovascular Diseases|Diabetes Mellitus
|
May 2010 | Phase 2 |
| NCT03929744 | Eli Lilly and Company |
Healthy
|
June 12, 2019 | Phase 1 |
| NCT01013103 | Hippocration General Hospital |
Coronary Artery Disease|HMG-CoA Reductase Inhibitor Toxicity|Atherosclerosis|Oxidative Stress|Endothelial Dysfunction
|
October 2007 | Phase 4 |
| NCT05806723 | Hopital La Rabta |
Diabetes Mellitus, Type 2|Dyslipidemia Associated With Type II Diabetes Mellitus|Statin Adverse Reaction|Hypogonadism, Male|Adrenal Insufficiency|Vitamin D Deficiency
|
March 1, 2021 | Phase 4 |
| NCT02245087 | University Health Network, Toronto |
Coronary Artery Disease
|
August 2014 | Phase 2 |
| NCT01033058 | Beijing Chao Yang Hospital|Pfizer |
STEMI
|
December 2009 | Phase 4 |
| NCT03275376 | Taichung Veterans General Hospital |
Overall Survival|Tumor Responses
|
December 21, 2017 | Phase 2 |
| NCT00728013 | Ministry of Science and Technology of the People´s Republic of China |
Acute Coronary Syndrome
|
December 2006 | Not Applicable |
| NCT03073863 | Korea University Guro Hospital|Pfizer |
Cardiovascular Diseases
|
April 3, 1998 | Phase 4 |
| NCT03418974 | Fudan University|Peking University People´s Hospital|Jiangsu Wanbang Medicine Marketing Co., Ltd. |
Dyslipidemias
|
November 1, 2017 | Phase 4 |
| NCT01857921 | Yonsei University |
Coronary Artery
|
December 2010 | Not Applicable |
| NCT02767362 | UNC Lineberger Comprehensive Cancer Center|Wilma Williams Education and Clinical Research for Endometrial Cancer Award |
Endometrial Cancer
|
November 2015 | Early Phase 1 |
| NCT00654407 | AstraZeneca |
Hypercholesterolemia
|
November 2001 | Phase 3 |
| NCT01288443 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolemia
|
January 2011 | Phase 2 |
| NCT00689442 | Akros Pharma Inc. |
Dyslipidemia
|
January 2004 | Phase 2 |
| NCT02979704 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
Hyperlipidemia
|
September 2016 | Phase 2|Phase 3 |
| NCT00965055 | University of California, San Diego|Merck Sharp & Dohme LLC |
High Cholesterol|Coronary Artery Disease
|
September 2009 | Phase 3 |
| NCT00136942 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hyperlipidemia
|
April 2005 | Phase 3 |
| NCT02342015 | University of Padova |
Osteoporosis|Hypercholesterolemia
|
November 2012 | Phase 4 |
| NCT00126048 | University of Glasgow|NHS Greater Glasgow and Clyde|Asthma UK|NHS Greater Clyde and Glasgow |
Asthma
|
July 2005 | Phase 2|Phase 3 |
| NCT05103644 | Beni-Suef University |
Breast Cancer
|
October 30, 2021 | Phase 2|Phase 3 |
| NCT03247400 | Nicolaus Copernicus University |
Non-segmental Vitiligo
|
December 1, 2016 | Phase 1|Phase 2 |
| NCT00590135 | The Cleveland Clinic|Pfizer |
Aortic Valve Stenosis
|
August 2000 | Phase 4 |
| NCT05970679 | Daewon Pharmaceutical Co., Ltd. |
Hypercholesterolemia, Dyslipidemia
|
August 17, 2022 | Phase 3 |
| NCT03750760 | Imperial College London|Regeneron Pharmaceuticals|Baim Institute for Clinical Research |
Myocardial Infarction|Dyslipidemias
|
January 2020 | Phase 4 |
| NCT05679102 | Himayat Ullah|Ayub Teaching Hospital|Khyber Medical University Peshawar|Shaqra University |
Atorvastatin Antihypertensive Effect
|
December 20, 2022 | Not Applicable |
| NCT02089061 | Bristol-Myers Squibb |
Acute Coronary Syndromes
|
March 2014 | Phase 1 |
| NCT01806324 | HanAll BioPharma Co., Ltd. |
Hypertension|Hyperlipidemia
|
April 2012 | Phase 1 |
| NCT00690443 | Aegerion Pharmaceuticals, Inc. |
Hypercholesterolemia
|
May 2008 | Phase 2 |
| NCT01863225 | Resverlogix Corp|South Australian Health and Medical Research Institute |
Dyslipidemia|Coronary Artery Disease
|
May 2013 | Phase 2 |
| NCT02416427 | Regina Elena Cancer Institute |
Breast Neoplasms
|
May 2015 | Phase 2 |
| NCT00756886 | University of Alabama at Birmingham|Pfizer |
Arrhythmia
|
September 2008 | Not Applicable |
| NCT00166036 | Emory University |
Diabetes Mellitus|Metabolic Syndrome X|Hypercholesterolemia
|
September 2004 | Phase 2 |
| NCT01820767 | Ricardo Mouzo Mirco|Hospital El Bierzo |
Chronic Kidney Disease
|
August 2012 | Phase 3 |
| NCT05507398 | Tanta University |
Breast Cancer Female
|
October 2022 | Phase 4 |
| NCT02608697 | Catabasis Pharmaceuticals |
Hypercholesterolemia
|
October 2015 | Phase 2 |
| NCT01974297 | Sang Hak Lee|Yonsei University |
Mixed Hyperlipidemia
|
July 2013 | Not Applicable |
| NCT05180942 | Monash University|National Health and Medical Research Council, Australia |
Melanoma|Atherosclerosis
|
November 7, 2022 | Phase 2 |
| NCT00862251 | Organon and Co |
Cardiovascular Disorder|Diabetes Mellitus
|
April 2009 | Phase 3 |
| NCT01759836 | Asan Medical Center|Dong-A Pharmaceutical |
Prostatic Neoplasms
|
October 2012 | Phase 2 |
| NCT03801733 | Akebia Therapeutics |
Drug Interaction Potentiation
|
June 17, 2018 | Phase 1 |
| NCT01448174 | Poznan University of Medical Sciences |
Renal Failure Chronic Requiring Hemodialysis|Metabolic Syndrome|Diabetes Mellitus Type 2|Hyperlipidemia
|
October 2011 | Phase 4 |
| NCT02470455 | Shri Ramachandra Bhanj Medical College |
Prediabetic State
|
July 2011 | |
| NCT00344370 | Kowa Research Europe |
Type II Diabetes Mellitus|Dyslipidemia
|
August 2006 | Phase 3 |
| NCT01697735 | Wenzhou Medical University |
Dyslipidemias
|
September 2012 | Phase 4 |
| NCT04767984 | National Cancer Institute (NCI) |
Colorectal Carcinoma|Ulcerative Colitis
|
September 24, 2021 | Phase 2 |
| NCT03819101 | Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France |
Prostate Cancer
|
June 6, 2019 | Phase 3 |
| NCT04824911 | Chang Gung Memorial Hospital |
Acute Stroke|Dual Antiplatelet Therapy|Statin
|
March 23, 2021 | Phase 2 |
| NCT05792293 | Ain Shams University |
Doxorubicin Induced Cardiomyopathy
|
June 1, 2021 | Phase 2|Phase 3 |
| NCT03906539 | All India Institute of Medical Sciences, Bhubaneswar|Coconut Development Board, Government of India |
Dyslipidemias
|
May 22, 2019 | Phase 4 |
| NCT01218204 | GlaxoSmithKline |
Dyslipidaemias|Dyslipidemias
|
September 14, 2010 | Phase 2 |
| NCT01733953 | University of Minnesota |
Cardiovascular Disease|Childhood ALL|Childhood NHL
|
November 2012 | Phase 2 |
| NCT00654225 | AstraZeneca |
Hypercholesterolemia|Dyslipidaemia
|
October 2002 | Phase 3 |
| NCT01953328 | Amgen |
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
|
October 2013 | Phase 3 |
| NCT01491256 | The Korean Society of Circulation |
Acute Coronary Syndrome
|
February 2010 | Not Applicable |
| NCT00804843 | Merck Sharp & Dohme LLC |
Carotid Atherosclerosis
|
April 2009 | Phase 2 |
| NCT00926614 | Brooke Army Medical Center |
Hepatitis c
|
September 2008 | Phase 4 |
| NCT00110435 | Organon and Co |
Type 2 Diabetes Mellitus|Hypercholesterolemia
|
May 2005 | Phase 3 |
| NCT05306990 | Helwan University |
Hydroxymethylglutaryl-CoA Reductase Inhibitors|Diabetes Mellitus
|
April 20, 2017 | Not Applicable |
| NCT00395603 | Organon and Co |
Cardiovascular Diseases|Diabetes Mellitus
|
September 2006 | Phase 3 |
| NCT00991705 | Boryung Pharmaceutical Co., Ltd |
Essential Hypertension
|
July 2009 | Phase 1 |
| NCT03176498 | Sclnow Biotechnology Co., Ltd. |
Cerebral Infarction
|
December 2023 | Phase 1|Phase 2 |
| NCT00361283 | University of Florida|American Heart Association|American College of Clinical Pharmacy |
Inflammation
|
June 2004 | Phase 4 |
| NCT01214746 | Regional Hospital Holstebro |
Cardiovascular Diseases|Nephropathy
|
May 2010 | Phase 2 |
| NCT03464682 | Zhejiang Hisun Pharmaceutical Co. Ltd. |
Primary Hypercholesterolemia
|
February 28, 2015 | Phase 3 |
| NCT02496962 | Shi Yang|Chinese PLA General Hospital |
Sleep Deprivation
|
July 2015 | Not Applicable |
| NCT05504330 | Anhui Medical University |
Asymptomatic Intracranial Stenosis|Cognitive Impairment|Cerebrovascular Event
|
August 15, 2022 | |
| NCT01023607 | Harbin Medical University |
Coronary Artery Disease|Hyperlipidemia
|
December 2009 | Phase 4 |
| NCT01842256 | Chong Kun Dang Pharmaceutical |
Essential Hypertension|Hyperlipidemia
|
April 2013 | Phase 1 |
| NCT00195793 | Abbott |
Hyperlipidemia
|
August 2004 | Phase 3 |
| NCT00296400 | AstraZeneca |
Hyperlipidemia
|
February 2006 | Phase 2 |
| NCT01041729 | Hospital Universitario Getafe |
Peripheral Arterial Disease
|
January 2008 | Phase 4 |
| NCT03532620 | Jun Tao|Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University |
Prediabetic State|Hypertension|Dyslipidemias
|
August 9, 2018 | Phase 4 |
| NCT00987974 | Radboud University Medical Center |
Ischemia Reperfusion Injury|Endothelial Dysfunction
|
September 2009 | Phase 4 |
| NCT03867318 | Organon and Co |
Hypercholesterolemia
|
April 24, 2000 | Phase 3 |
| NCT05561062 | Tanta University |
Inflammatory Bowel Diseases
|
December 1, 2022 | Phase 2 |
| NCT02668016 | Imperial College London |
Adverse Effects|Cardiovascular Diseases|Hyperlipidemias
|
March 2016 | Phase 4 |
| NCT01335048 | Ospedale Misericordia e Dolce |
Stable Angina
|
April 2011 | Phase 4 |
| NCT04147286 | University of Cape Town|University of Zurich|University of Namibia|University of Bern|University of Stellenbosch |
Tuberculosis, Pulmonary
|
July 14, 2020 | Phase 2|Phase 3 |
| NCT02726555 | Wenzhou Medical University |
Dyslipidemia|Atherosclerosis
|
November 2015 | Phase 3 |
| NCT01058057 | University Hospital, Motol |
Coronary Artery Disease|Coronary Angioplasty
|
February 2008 | Phase 3 |
| NCT01548326 | Nematollah Jonaidi Jafari|Baqiyatallah Medical Sciences University |
Hepatitis B|Vaccination Failure
|
September 2011 | Phase 4 |
| NCT03753555 | General Hospital of Shenyang Military Region |
Stroke, Ischemic|Atherosclerosis, Cerebral
|
December 1, 2018 | Phase 4 |
| NCT01285544 | Seoul National University Hospital|Dong-A Pharmaceutical |
Dyslipidemia|Cardiovascular Disease|Hypercholesterolemia
|
September 2008 | Phase 4 |
| NCT00154024 | Technische Universität Dresden |
Healthy Subjects
|
March 2003 | Not Applicable |
| NCT01997294 | Zhang Qi, MD|Shanghai Jiao Tong University School of Medicine |
Acute Myocardial Infarction
|
January 2013 | Not Applicable |
| NCT01550419 | Shanghai Minhang Central Hospital|Shanghai Jiao Tong University School of Medicine |
Ventilator-associated Pneumonia|Ischemic Stroke
|
March 2012 | Early Phase 1 |
| NCT00666029 | University Hospital Southampton NHS Foundation Trust |
Metabolic Syndrome
|
February 2006 | Phase 2 |
| NCT01526460 | IRCCS San Raffaele |
Platelet Dysfunction
|
August 2011 | Phase 2 |
| NCT04591808 | Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier |
Dyslipidemias|Hypertension
|
September 9, 2021 | Phase 3 |
| NCT00286312 | R&D Cardiologie|UMC Utrecht |
Myocardial Infarction|Reperfusion Injury
|
February 2006 | Phase 4 |
| NCT00772564 | Rambam Health Care Campus|Pfizer |
Myocardial Infarction
|
August 2008 | Phase 4 |
| NCT04850001 | Anhui Medical University |
Magnetic Resonance Imaging|Asymptomatic Intracranial Stenosis|Medical Treatment
|
September 10, 2020 | |
| NCT00120133 | Children´s Mercy Hospital Kansas City |
Osteoporosis
|
December 2004 | Not Applicable |
| NCT02166593 | Yooyoung Pharmaceutical Co., Ltd. |
Combined Dyslipidemia
|
May 2014 | Phase 3 |
| NCT00549926 | Yokohama City University Medical Center |
Coronary Disease|Hypercholesterolemia
|
October 2007 | Phase 4 |
| NCT02957162 | University Hospitals of North Midlands NHS Trust |
Acute Coronary Syndrome
|
March 2016 | Phase 4 |
| NCT00120055 | University of Oslo School of Pharmacy |
Myopathy
|
February 2005 | Phase 4 |
| NCT00367458 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
HIV
|
October 18, 2006 | Phase 2 |
| NCT02550288 | Organon and Co |
Hypercholesterolemia
|
September 29, 2015 | Phase 3 |
| NCT02243098 | Novo Nordisk A+S |
Diabetes|Healthy
|
September 16, 2014 | Phase 1 |
| NCT00309751 | Kowa Research Europe |
Type II Diabetes Mellitus|Dyslipidemia
|
December 2005 | Phase 3 |
| NCT00392717 | The University of Western Australia |
Obesity|Dyslipidemia|Insulin Resistance
|
February 1998 | Phase 3 |
| NCT01732718 | University of North Carolina, Chapel Hill|National Heart, Lung, and Blood Institute (NHLBI) |
Sickle Cell Disease|Sickle Cell Nephropathy
|
September 2013 | Phase 2 |
| NCT04472637 | Alexandria University |
Arterial Stiffness
|
November 1, 2020 | Phase 2 |
| NCT01306565 | Hormozgan University of Medical Sciences |
Cardiovascular Disease
|
January 2009 | Not Applicable |
| NCT01645423 | Dr. Reddy´s Laboratories Limited |
Healthy
|
August 2009 | Phase 1 |
| NCT00965185 | Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI) |
Cardiovascular Disease|HIV|Atherosclerosis|Inflammation|Statins, HMG-CoA|HIV Infections
|
September 2009 | Not Applicable |
| NCT00335504 | National Cancer Institute (NCI) |
Colon Cancer|Precancerous Condition|Rectal Cancer
|
March 2006 | Phase 2 |
| NCT05030818 | Fundación para la Investigación Biosanitaria del Principado de Asturias |
Coronary Artery Disease
|
October 14, 2022 | Phase 4 |
| NCT01547455 | Peking Union Medical College|Chinese Academy of Medical Sciences, Fuwai Hospital |
Acute Kidney Injury
|
April 2012 | Not Applicable |
| NCT04882293 | Laboratorios Silanes S.A. de C.V. |
Dyslipidemia Associated With Type II Diabetes Mellitus
|
February 15, 2022 | Phase 3 |
| NCT00990808 | Merck Sharp & Dohme LLC |
Dyslipidemia
|
November 2009 | Phase 1 |
| NCT00242944 | Kyoto University|Yamaguchi University Hospital|Juntendo University|Kyoto University Hospital |
Coronary Disease|Hypercholesterolemia
|
November 2005 | Phase 4 |
| NCT00827606 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Familial Hypercholesterolemia
|
March 2009 | Phase 3 |
| NCT00235950 | AstraZeneca |
Coronary Heart Disease
|
January 2004 | Phase 4 |
| NCT00572312 | Medical University of Gdansk |
Chronic Kidney Disease|Proteinuria
|
February 2005 | Not Applicable |
| NCT00000941 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
Phase 1 | |
| NCT00979758 | Chinese Academy of Medical Sciences, Fuwai Hospital |
Myocardial Infarction|Stem Cell Transplantation|Angioplasty, Transluminal, Percutaneous Coronary
|
January 2009 | Phase 2 |
| NCT00134173 | Pfizer |
Coronary Disease|Coronary Arteriosclerosis|Hyperlipidemia
|
October 2003 | Phase 3 |
| NCT02910778 | Medical University of Vienna |
Ischemia
|
October 2016 | Phase 4 |
| NCT01946815 | Keimyung University Dongsan Medical Center|Seoul National University Hospital|Ulsan University Hospital|Inje University Ilsan Paik Hospital |
Coronary Artery Disease
|
September 2013 | Phase 3 |
| NCT00917527 | Yonsei University |
Coronary Heart Disease
|
June 2009 | Phase 4 |
| NCT00412841 | NYU Langone Health |
Avascular Necrosis
|
November 2002 | Phase 2 |
| NCT01528709 | Boca Raton Regional Hospital|Pfizer |
Saphenous Vein Graft Disease
|
March 2012 | Phase 3 |
| NCT00469326 | University Hospital, Motol |
Coronary Artery Disease
|
April 2005 | Phase 3 |
| NCT00751907 | University of Wisconsin, Madison|National Institute on Aging (NIA) |
Alzheimer´s Disease
|
June 2006 | Phase 2 |
| NCT04984616 | Juan D. Maya|University of Chile |
Chronic Chagas Disease
|
October 12, 2021 | Phase 2 |
| NCT00669695 | University Hospital, Grenoble |
Obstructive Sleep Apnea Syndrome
|
May 2008 | Phase 2 |
| NCT01105975 | Eli Lilly and Company |
Dyslipidemia
|
April 2010 | Phase 2 |
| NCT01761656 | Central South University |
Stable Angina|Unstable Angina|Acute Non-ST-segment Elevation Myocardial Infarction
|
December 2012 | Phase 2 |
| NCT03051100 | Esperion Therapeutics, Inc. |
Hypercholesterolemia
|
January 19, 2017 | Phase 2 |
| NCT00454545 | Skane University Hospital |
Crohns Disease
|
October 2006 | Phase 2 |
| NCT05839236 | Yang I. Pachankis|Pachankis, Yang I., M.D. |
COVID-19 Stress Syndrome|COVID-19 Vaccine Adverse Reaction|COVID-19-Associated Thromboembolism|COVID-19 Post-Intensive Care Syndrome|COVID-19-Associated Stroke|COVID-19 Respiratory Infection
|
May 1, 2023 | Phase 1 |
| NCT02364258 | Children´s Mercy Hospital Kansas City |
Dyslipidemia
|
July 2014 | Phase 1 |
| NCT04863274 | The League of Clinical Research, Russia|National Research Center for Preventive Medicine |
Lipid Metabolism Disorders
|
June 21, 2018 | |
| NCT04056039 | Hospital Central Dr. Ignacio Morones Prieto |
Cardiovascular Diseases|Arthritis, Rheumatoid
|
August 14, 2018 | Phase 2 |
| NCT05730634 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Diabetes Mellitus, Type 2|Vascular Inflammation
|
June 1, 2019 | Not Applicable |
| NCT00973271 | Essentialis, Inc. |
Hypertriglyceridemia
|
March 2011 | Phase 3 |
| NCT01363999 | Hoffmann-La Roche |
Healthy Volunteer
|
June 2011 | Phase 1 |
| NCT00587379 | Mayo Clinic|Pfizer |
Endothelial Dysfunction
|
June 2004 | Not Applicable |
| NCT03461081 | Jeil Pharmaceutical Co., Ltd. |
Hypertension With Hyperlipidemia
|
May 7, 2017 | Phase 1 |
| NCT02685462 | Tobira Therapeutics, Inc. |
Healthy
|
January 31, 2016 | Phase 1 |
| NCT02706860 | Cairo University |
Coronary Artery Bypass Grafting
|
June 2013 | Phase 4 |
| NCT02386033 | Government Dental College and Research Institute, Bangalore |
Chronic Periodontitis
|
November 2013 | Phase 2|Phase 3 |
| NCT01763866 | Amgen |
Hyperlipidemia
|
January 15, 2013 | Phase 3 |
| NCT03072082 | Jun Li|China Academy of Chinese Medical Sciences|Guang´anmen Hospital of China Academy of Chinese Medical Sciences |
Coronary Artery Disease(CAD)
|
June 2017 | Phase 4 |
| NCT02066207 | Chong Kun Dang Pharmaceutical |
Dyslipidemia (Fredrickson Type ?a)|Dyslipidemia (Fredrickson Type ?b)
|
March 18, 2014 | Phase 1 |
| NCT01984424 | Amgen |
Hyperlipidemia
|
December 10, 2013 | Phase 3 |
| NCT03872388 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2+Neu Negative|Inflammatory Breast Carcinoma|Progesterone Receptor Negative|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
|
January 14, 2019 | Phase 2 |
| NCT00942591 | Insel Gruppe AG, University Hospital Bern|PharmaPart|Laboratory: Viollier AG Spalenring 145 + 147 Postfach 4002 Basel |
Multiple Sclerosis
|
May 2005 | Phase 2 |
| NCT00252967 | Emory University|Pfizer |
Atrial Fibrillation|Inflammation
|
October 2005 | Phase 3 |
| NCT00734123 | Hospital Arnau de Vilanova|Pfizer |
Atherosclerosis|Cardiovascular Diseases
|
April 2008 | Phase 4 |
| NCT05826912 | University of California, San Francisco|United States Department of Defense |
Traumatic Brain Injury
|
August 30, 2023 | Phase 2 |
| NCT00616187 | Charite University, Berlin, Germany|German Research Foundation|German Federal Ministry of Education and Research|Pfizer |
Relapsing Remitting Multiple Sclerosis
|
October 2003 | Phase 2 |
| NCT05675787 | Peking University People´s Hospital |
Atypical Endometrial Hyperplasia|Endometrial Carcinoma Stage I
|
January 6, 2023 | Phase 2 |
| NCT04375787 | Mohamed Abdelfatah|Assiut University |
Coronary Disease
|
March 15, 2020 | Phase 4 |
| NCT01448642 | Hospital do Coracao|Ministry of Health, Brazil |
Acute Coronary Syndrome
|
April 2012 | Phase 4 |
| NCT00359281 | Aegerion Pharmaceuticals, Inc. |
Healthy
|
March 2006 | Phase 2 |
| NCT01929135 | Universidad de los Andes, Chile|Corporación de Fomento de la Producción, Chile |
Chronic Periodontitis
|
May 2013 | Phase 2 |
| NCT00163202 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|MDS Pharma Services|Bio-Inova Life Sciences International|Pfizer |
Coronary Arteriosclerosis|Hypercholesterolemia
|
June 2002 | Phase 4 |
| NCT01299181 | University of Edinburgh|NHS Lothian |
Bronchiectasis
|
November 2010 | Phase 4 |
| NCT02189837 | Amgen |
Primary Hyperlipidemia and Mixed Dyslipidemia
|
July 8, 2014 | Phase 3 |
| NCT00723320 | Ministry of Science and Technology of the People´s Republic of China|Peking University First Hospital |
Atherosclerosis
|
February 2008 | Not Applicable |
| NCT03482180 | Kuhnil Pharmaceutical Co., Ltd. |
Dyslipidemias
|
May 4, 2016 | Phase 3 |
| NCT01257009 | UMC Utrecht |
Stable Chronic Kidney Disease|Hypertension
|
August 2009 | Phase 4 |
| NCT02994745 | Boryung Pharmaceutical Co., Ltd |
Hypertension, Hyperlipidemia
|
December 23, 2016 | Phase 1 |
| NCT00517257 | University of Toronto|Unity Health Toronto|Pfizer|Canadian Heart Research Centre|Ontario Association of Optometrists|Toronto Ophthalmological Society |
Retinal Vein Occlusion|Retinal Vein Thrombosis|Central Retinal Vein Occlusion|Branch Retinal Vein Occlusion|Thrombosis
|
August 2007 | Phase 3 |
| NCT00651378 | Organon and Co|Merck Sharp & Dohme LLC |
Hypercholesterolemia|Atherosclerosis|Coronary Artery Disease
|
September 1, 2004 | Phase 4 |
| NCT00793754 | Fundacion GESICA |
Diabetes Mellitus
|
March 2009 | Phase 4 |
| NCT02586155 | Resverlogix Corp|PPD|ICON plc|Medidata Solutions |
Diabetes Mellitus, Type 2|Coronary Artery Disease
|
November 2015 | Phase 3 |
| NCT03867110 | Organon and Co |
Hypercholesterolemia
|
March 6, 2000 | Phase 3 |
| NCT00675779 | Poznan University of Medical Sciences|University of California, Davis|Biomet Polska Sp. z.o.o. |
Endometriosis|Pain
|
April 2008 | Not Applicable |
| NCT02863185 | Dong-A University |
Chronic Kidney Disease
|
May 1, 2016 | Phase 4 |
| NCT00902967 | B. J. Medical College, Pune |
Abdominal Surgery
|
July 2009 | Phase 3 |
| NCT00644670 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Dyslipidemias
|
June 2003 | Phase 4 |
| NCT01166633 | JW Pharmaceutical |
Hypercholesterolemia
|
June 2009 | Phase 4 |
| NCT02633956 | Intercept Pharmaceuticals |
Nonalcoholic Steatohepatitis
|
December 4, 2015 | Phase 2 |
| NCT04379999 | Fox Chase Cancer Center |
Lynch Syndrome
|
September 10, 2018 | Early Phase 1 |
| NCT01572623 | Campus Bio-Medico University |
Carotid Stenosis
|
July 2011 | Phase 4 |
| NCT02093390 | Millennium Pharmaceuticals, Inc. |
Prostate Cancer|Endometriosis
|
March 2014 | Phase 1 |
| NCT01050348 | The Western Pennsylvania Hospital|West Penn Allegheny Health System |
Acute Myocardial Infarction
|
June 2009 | Phase 4 |
| NCT00243672 | University Hospital Muenster |
Atherosclerosis
|
October 2005 | Phase 4 |
| NCT00120887 | Johns Hopkins University|Lupus Research Alliance |
Systemic Lupus Erythematosus
|
April 2002 | Phase 4 |
| NCT00496730 | Organon and Co |
Hypercholesterolemia
|
July 2007 | Phase 3 |
| NCT04608344 | Gilead Sciences|Galapagos NV |
Rheumatoid Arthritis
|
November 4, 2020 | Phase 1 |
| NCT00134485 | Pfizer |
Hypercholesterolemia, Familial|Hyperlipidemia
|
March 2005 | Phase 3 |
| NCT04801940 | Cambridge University Hospitals NHS Foundation Trust|University of Liverpool|Cambridge University Hospitals NHS Foundation Trust (joint Sponsor)|The University of Cambridge (joint Sponsor) |
Covid19
|
May 19, 2021 | Phase 3 |
| NCT00967434 | Ottawa Hospital Research Institute|Canadian Anesthesiologists´ Society|Heart and Stroke Foundation of Ontario |
Inflammation|Myocardial Infarction|Myocardial Ischemia
|
December 2007 | Not Applicable |
| NCT01322711 | University of Roma La Sapienza |
Type 2 Diabetes Mellitus|Hypercholesterolemia
|
March 2011 | Phase 4 |
| NCT00920101 | National Defense Medical College, Japan |
Atherosclerosis|Inflammation
|
June 2009 | Phase 4 |
| NCT00327691 | Pfizer |
Cardiovascular Disease|Cerebrovascular Accident|Coronary Heart Disease
|
April 1998 | Phase 4 |
| NCT01372839 | Xijing Hospital |
Myocardial Infarction|Unstable Angina
|
July 2010 | Phase 4 |
| NCT00687271 | Merck Sharp & Dohme LLC |
Hypercholesterolemia
|
June 14, 2008 | Phase 2 |
| NCT01780948 | Chulalongkorn University|Ratchadapiseksompotch Research Fund |
Difference of 12-hour AUC
|
September 2012 | Not Applicable |
| NCT02192320 | Oriental Neurosurgery Evidence-Based-Study Team |
Chronic Subdural Hematoma
|
July 2014 | Phase 2 |
| NCT01503671 | National Taiwan University Hospital |
Heart Failure
|
November 2011 | Phase 4 |
| NCT00134498 | Pfizer |
Hypertriglyceridemia|Hyperlipoproteinemia Type IV
|
February 2005 | Phase 3 |
| NCT00153166 | Brigham and Women´s Hospital|National Heart, Lung, and Blood Institute (NHLBI) |
Arterial Occlusive Disease|Intermittent Claudication|Insulin Resistance
|
January 2004 | Phase 2|Phase 3 |
| NCT02503865 | Nazarbayev University|Institute Of Cardiology & Internal Diseases, Kazakhstan |
Metabolic Syndrome
|
January 2003 | Phase 1|Phase 2 |
| NCT01495013 | GlaxoSmithKline |
Diabetes Mellitus, Type 2
|
December 2011 | Phase 3 |
| NCT00541697 | Organon and Co |
Diabetes Mellitus, Type 2
|
January 19, 2005 | Phase 3 |
| NCT01870804 | Centro Cardiopatici Toscani |
Acute Coronary Syndrome
|
May 2013 | Phase 4 |
| NCT04262765 | Midas Pharma GmbH |
Healthy Volunteers
|
February 23, 2019 | Phase 1 |
| NCT01665677 | Mehdi Hamadani|West Virginia University|Medical College of Wisconsin |
Graft vs Host Disease
|
January 20, 2014 | Phase 2 |
| NCT04666389 | I.M. Sechenov First Moscow State Medical University |
Contrast-induced Acute Kidney Injury|Cardiovascular Diseases
|
October 15, 2020 | Not Applicable |
| NCT04262206 | Duke University|National Institute on Aging (NIA)|National Heart, Lung, and Blood Institute (NHLBI)|Wake Forest University Health Sciences |
Cognitive Impairment, Mild|Dementia|Cardiovascular Diseases
|
September 1, 2020 | Phase 4 |
| NCT00665834 | Queen´s University|AstraZeneca |
Dyslipidemia|Acute Coronary Syndromes
|
April 2006 | Phase 4 |
| NCT05331053 | Penn State University |
Endometriosis
|
May 1, 2018 | Phase 4 |
| NCT04754789 | Assiut University |
ST Elevation Myocardial Infarction
|
February 20, 2021 | Phase 3 |
| NCT02662569 | Amgen |
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
|
April 14, 2016 | Phase 3 |
| NCT01394848 | Yonsei University|OrbusNeich|Yuhan Corporation |
Stable Angina
|
October 2011 | Phase 4 |
| NCT05250596 | Azienda USL Toscana Centro |
Non ST Segment Elevation Acute Coronary Syndrome
|
February 24, 2022 | Phase 2 |
| NCT01617538 | Capital Medical University |
Stenosis
|
January 2012 | Phase 1|Phase 2 |
| NCT00157924 | Organon and Co |
Hypercholesterolemia
|
November 2005 | Phase 4 |
| NCT03072121 | Jun Li|Shanghai Hutchison Pharmaceuticals Limited|Guang´anmen Hospital of China Academy of Chinese Medical Sciences |
Coronary Artery Disease(CAD)
|
June 2017 | Phase 4 |
| NCT00442325 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Coronary Arteriosclerosis|Diabetes Mellitus, Type 2|Cerebrovascular Accident|Dyslipidemia|Peripheral Vascular Disease
|
January 2003 | Phase 4 |
| NCT03885921 | Organon and Co |
Hypercholesterolemia
|
October 25, 2000 | Phase 3 |
| NCT03956368 | Chinese University of Hong Kong |
Chronic Subdural Hematoma
|
January 9, 2020 | Phase 3 |
| NCT00632840 | The University of Western Australia|National Heart Foundation, Australia |
Obesity|Lipid Disorders|Hypertriglyceridemia|Cardiovascular Disease
|
June 2001 | Phase 4 |
| NCT03188978 | Albany Medical College |
Primary Arteriovenous Fistula Failure
|
November 1, 2018 | Phase 1|Phase 2 |
| NCT02185066 | HK inno.N Corporation |
Healthy Volunteers
|
July 2014 | Phase 1 |
| NCT00151502 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Alzheimer´s Disease
|
November 2002 | Phase 3 |
| NCT04765137 | Johns Hopkins University |
Mild Cognitive Impairment
|
May 21, 2021 | Phase 2 |
| NCT00491400 | Boston University |
Diabetes Mellitus|Metabolic Syndrome
|
September 2005 | Not Applicable |
| NCT00437892 | Università degli Studi dell´Insubria |
Venous Thromboembolism|Hypercholesterolemia
|
May 2007 | Phase 2 |
| NCT03004001 | Gloria Vega|Regeneron Pharmaceuticals|Aventis Pharmaceuticals|Dallas VA Medical Center |
Nephrotic Syndrome
|
January 2017 | Phase 2 |
| NCT01518166 | Novo Nordisk A+S |
Diabetes|Healthy
|
May 2006 | Phase 1 |
| NCT02591836 | NeuroBo Pharmaceuticals Inc. |
Hypercholesterolemia
|
January 2003 | Phase 2 |
| NCT02099123 | Monash University|National Health and Medical Research Council, Australia|National Heart Foundation, Australia |
Independent Living|Disability Free Survival|Elderly|Healthy
|
July 2015 | Phase 4 |
| NCT04486508 | Rajaie Cardiovascular Medical and Research Center|Brigham and Women´s Hospital|Tehran Heart Center|Masih Daneshvari Hospital|Hazrat Rasool Hospital|Modarres Hospital|Firuzgar hospital affiliated to Iran University of Medical Sciences|Imam Khomeini Hospital|Sina Hospital, Iran|Tabriz University of Medical Sciences|Shariati Hospital|Imam Ali Hospital|Labbafinejhad Hospital |
Covid19
|
July 30, 2020 | Phase 3 |
| NCT02764736 | Albert Einstein Healthcare Network |
Complication of Renal Dialysis
|
March 4, 2016 | Not Applicable |
| NCT02455869 | Government Dental College and Research Institute, Bangalore |
Chronic Periodontitis
|
July 2014 | Phase 2|Phase 3 |
| NCT05589454 | Sichuan Provincial People´s Hospital|Science & Technology Department of Sichuan Province |
Acute Ischemic Stroke|Cerebral Microbleeds
|
January 2023 | Phase 4 |
| NCT00610545 | University of Campinas, Brazil |
Vascular Surgery
|
July 2007 | Phase 4 |
| NCT01499771 | Ranbaxy Laboratories Limited|Ranbaxy Inc. |
Healthy
|
October 2009 | Phase 1 |
| NCT02714569 | Eli Lilly and Company |
Dyslipidemias
|
March 2016 | Phase 1 |
| NCT04904536 | The George Institute|University of Sydney|Monash University|The Alfred|Universidad del Desarrollo |
Neurocognitive Impairment, Mild
|
March 10, 2022 | Phase 3 |
| NCT01497912 | Karolinska Institutet |
Type 1 Diabetes Mellitus|Dyslipidemia
|
January 2005 | Phase 4 |
| NCT01779453 | Esperion Therapeutics, Inc. |
Hypercholesterolemia
|
December 2012 | Phase 2 |
| NCT00233480 | University of California, Los Angeles|Pfizer|National Heart, Lung, and Blood Institute (NHLBI) |
Heart Failure, Congestive
|
August 2005 | Phase 4 |
| NCT03122639 | Columbia University|National Heart, Lung, and Blood Institute (NHLBI) |
Obstructive Sleep Apnea of Adult
|
September 1, 2017 | Early Phase 1 |
| NCT03047772 | Yuejin Yang|Peking Union Medical College Hospital|The First Hospital of Hebei Medical University|Zunyi Medical College|Chinese Academy of Medical Sciences, Fuwai Hospital |
Myocardial Infarction|Stem Cell Transplantation|Angioplasty, Transluminal, Percutaneous Coronary
|
March 6, 2018 | Phase 2 |
| NCT04101136 | Dr Cipto Mangunkusumo General Hospital |
CMV
|
September 30, 2019 | Not Applicable |
| NCT00739999 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Pediatric Heterozygous Hypercholesterolemia
|
December 2008 | Phase 1 |
| NCT04026230 | Tampere University Hospital|Turku University Hospital|Central Finland Hospital District|Tartu University Hospital|University of Aarhus|Fimlab laboratories|Helsinki University Central Hospital|Kuopio University Hospital|Oulu University Hospital|Seinajoki Central Hospital|The Hospital of Vestfold|Telemark Hospital Trust |
Metastatic Prostate Cancer|Recurrent Prostate Cancer
|
August 15, 2019 | Phase 3 |
| NCT04661709 | Guang´anmen Hospital of China Academy of Chinese Medical Sciences|Special Project of National Traditional Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine|National Natural Science Foundation of China |
Coronary Heart Disease|Unstable Angina|Chinese Herbal Medicine
|
March 1, 2021 | Phase 4 |
| NCT00654485 | AstraZeneca |
Metabolic Syndrome
|
May 2002 | Phase 3 |
| NCT01431105 | University of California, San Diego|Children´s Hospital Colorado|University of Colorado, Denver |
Kawasaki Disease
|
July 2012 | Phase 1|Phase 2 |
| NCT01648829 | University of Roma La Sapienza |
Coronary Artery Disease
|
January 2014 | Phase 4 |
| NCT01186289 | Duke University|Pfizer |
Neurocognitive Dysfunction
|
October 2010 | Not Applicable |
| NCT00536887 | Korea University Anam Hospital |
Acute Myocardial Infarction
|
July 2005 | Phase 4 |
| NCT00844376 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypercholesterolemia
|
February 2008 | Phase 4 |
| NCT00644709 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Dyslipidemias
|
September 2003 | Phase 4 |
| NCT00449410 | Radboud University Medical Center|Pfizer|Schering-Plough |
Atrial Fibrillation|Neuropsychology|Magnetic Resonance Imaging|Inflammation|Hemostasis
|
May 2005 | Phase 4 |
| NCT03696940 | Laboratorios Grossman, S.A.|Instituto Nacional de Salud Publica, Mexico |
Dyslipidemias|Cardiovascular Risk Factor
|
May 28, 2018 | Phase 3 |
| NCT01228227 | Gennaro Sardella|University of Roma La Sapienza |
Assess the Periprocedural Myocardial Necrosis
|
October 2010 | Phase 3 |
| NCT00910221 | Austin Health |
Acute Kidney Dysfunction
|
March 2008 | Phase 2|Phase 3 |
| NCT00911339 | IRCCS Policlinico S. Matteo |
Stable Coronary Artery Disease
|
January 2009 | Phase 3 |
| NCT04601116 | Aarhus University Hospital|Rigshospitalet, Denmark|Hospital of Southern Jutland|University of Copenhagen|Bornholms Hospital|Naestved Hospital|Vejle Hospital|Odense University Hospital|Nordsjaellands Hospital|Aalborg University Hospital|Herning Hospital |
Breast Cancer Female|Estrogen Receptor Positive Tumor
|
January 4, 2021 | Phase 3 |
| NCT01987310 | Sheba Medical Center |
Non Alcoholic Fatty Liver Disease
|
December 2015 | Not Applicable |
| NCT00616772 | AbbVie (prior sponsor, Abbott)|AbbVie |
Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia
|
February 2008 | Phase 3 |
| NCT00300469 | Abbott |
Mixed Dyslipidemia|Coronary Heart Disease|Dyslipidemia
|
March 2006 | Phase 3 |
| NCT02497638 | University Health Network, Toronto |
Prostate Cancer
|
December 2021 | Phase 2 |
| NCT05464628 | Gannex Pharma Co., Ltd. |
Healthy
|
August 8, 2022 | Phase 1 |
| NCT04251364 | Centre d´Expertise sur l´Altitude EXALT |
Hypoxia, Altitude
|
February 15, 2020 | Not Applicable |
| NCT00681525 | Abbott |
Pharmacokinetics
|
April 2008 | Phase 1 |
| NCT00645151 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Dyslipidemias
|
April 2004 | Phase 4 |
| NCT05093205 | Pfizer |
Healthy Adults
|
October 25, 2021 | Phase 1 |
| NCT00808717 | Yonsei University |
Myocardial Infarction|Angioplasty|Percutaneous Coronary
|
July 2007 | Phase 4 |
| NCT01250834 | Eli Lilly and Company |
Healthy Volunteers
|
December 2010 | Phase 1 |
| NCT00481364 | Ercan OK|Pfizer|Ege University |
Vascular Calcification|Atherosclerosis|Dyslipidemia|Inflammation
|
November 2006 | Phase 3 |
| NCT02022293 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Nasopharyngeal Carcinoma|Radiation Therapy Complication
|
January 2017 | Phase 2 |
| NCT00844402 | Medical University of Graz |
Primary Biliary Cirrhosis|Hypercholesterolemia
|
January 2006 | Phase 3 |
| NCT00403533 | Massachusetts General Hospital |
Hepatitis C
|
February 2006 | Phase 2 |
| NCT00917644 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypercholesterolemia
|
July 2008 | Phase 4 |
| NCT01812707 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolemia
|
March 2013 | Phase 2 |
| NCT00427960 | AstraZeneca |
Hypercholesterolaemia
|
December 2006 | Phase 4 |
| NCT00150371 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypercholesterolemia
|
June 2004 | Phase 3 |
| NCT01956201 | Chong Kun Dang Pharmaceutical |
Mixed Hyperlipidemia
|
December 2013 | Phase 3 |
| NCT01525407 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Malignant Neoplasm
|
May 2012 | Phase 2 |
| NCT00409773 | Organon and Co |
Hypercholesterolemia|Metabolic Syndrome
|
January 2007 | Phase 3 |
| NCT02850081 | Columbia University |
Carotid Artery Stenosis|Strokes
|
June 1, 2017 | Phase 3 |
| NCT00576576 | Emory University|Pfizer |
Atherosclerosis
|
July 2007 | Not Applicable |
| NCT03874156 | Vestre Viken Hospital Trust|The Hospital of Vestfold|Oslo University Hospital|University of Oslo |
Statin Adverse Reaction
|
March 5, 2019 | Phase 4 |
| NCT03031119 | Pfizer |
Healthy Volunteers
|
January 2017 | Phase 1 |
| NCT02603328 | University of Chicago|Johns Hopkins University |
Cerebral Cavernous Malformation
|
July 17, 2018 | Phase 1|Phase 2 |
| NCT01213498 | Erling Bjerregaard Pedersen|Regional Hospital Holstebro |
Nephropathy|Cardiovascular Diseases
|
May 2010 | Phase 2 |
| NCT00138762 | Pfizer |
Hyperlipidemia
|
July 2004 | Phase 3 |
| NCT00141141 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypercholesterolemia
|
January 2004 | Phase 4 |
| NCT03560882 | Joaquina Baranda|University of Kansas Medical Center |
Malignant Disease|Solid Tumor|Acute Myeloid Leukemia|Myelodysplastic Syndromes|Cancer|Relapsed Hematologic Malignancy
|
July 19, 2018 | Phase 1 |
| NCT02094313 | University Hospital, Clermont-Ferrand|Service de Biologie de la Reproduction : AMP-CECOS|EA 975, Laboratoire de BDR|Service d´Endocrinologie, Diabète et Maladies Métaboliques|Laboratoire d´Hormonologie - Biochimie |
Healthy Volunteers|Normocholesterolaemic Men|Normozoospermic Men
|
January 2008 | Phase 1 |
| NCT00092690 | Organon and Co |
Hypercholesterolemia
|
June 2003 | Phase 3 |
| NCT05764317 | Servier Russia |
Arterial Hypertension|HTN
|
April 30, 2023 | |
| NCT00024531 | Institute for the Study of Aging (ISOA)|Pfizer|National Institute on Aging (NIA) |
Alzheimer Disease
|
October 2000 | Phase 2 |
| NCT00631189 | AstraZeneca |
Type IIa and IIb Hypercholesterolaemia
|
October 2007 | Phase 4 |
| NCT01624207 | Seoul National University Hospital|Yuhan corp., Seoul, Korea |
Hypercholesterolemia
|
March 2010 | Phase 4 |
| NCT05511766 | Tanta University |
Cirrhosis|Hepatic Encephalopathy|Ascites|Varices|SBP - Spontaneous Bacterial Peritonitis
|
November 15, 2022 | Phase 2|Phase 3 |
| NCT00276133 | Yokohama City University Medical Center |
Chronic Nephropathy
|
January 2004 | Phase 4 |
| NCT00770796 | Ospedale Misericordia e Dolce |
Contrast Induced Nephropathy
|
April 2006 | Phase 4 |
| NCT01386853 | Tai Tien Pharmaceuticals Co., Ltd. |
Hyperlipidemia
|
July 2011 | Phase 3 |
| NCT00818103 | Sun Yat-sen University|Third Affiliated Hospital, Sun Yat-Sen University |
Multiple Sclerosis
|
January 2006 | Not Applicable |
| NCT01013870 | Baylor College of Medicine|The University of Texas Health Science Center, Houston |
Traumatic Brain Injury|Post-traumatic Stress Disorder
|
February 2010 | Phase 2 |
| NCT01096875 | Ankara University|Turkish Society of Hematology |
Coronary Artery Bypass Surgery|Elective Surgical Procedure
|
February 2010 | Phase 4 |
| NCT05641753 | NYU Langone Health|National Heart, Lung, and Blood Institute (NHLBI) |
Type 1 Diabetes
|
December 6, 2022 | Phase 4 |
| NCT04181749 | University of Leicester|University of Oxford|British Heart Foundation|National Institute for Health Research, United Kingdom |
Cardiovascular Risk Factor
|
November 18, 2020 | Phase 2 |
| NCT00441597 | Radboud University Medical Center|Pfizer |
Ischemia Reperfusion Injury|Cardiovascular Disease
|
February 2007 | Phase 4 |
| NCT02097589 | University of Florida |
Healthy Controls
|
June 2014 | Phase 1 |
| NCT01200056 | Prof. Stephen Lee|Queen Mary Hospital, Hong Kong|Pfizer|The University of Hong Kong |
Coronary Disease|Ultrasonography, Interventional|Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
August 2007 | Phase 4 |
| NCT04915183 | National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC) |
Hearing Loss|Head and Neck Cancer
|
August 27, 2023 | Phase 3 |
| NCT01477853 | Merck Sharp & Dohme LLC |
Type 2 Diabetes Mellitus
|
October 24, 2011 | Phase 3 |
| NCT04735263 | Massachusetts Eye and Ear Infirmary |
Age-related Macular Degeneration
|
February 4, 2021 | Phase 2 |
| NCT02056340 | Beth Israel Deaconess Medical Center|National Institute of General Medical Sciences (NIGMS) |
Influenza
|
October 2013 | Phase 2 |
| NCT01073800 | University of Alberta |
Myocardial Infarction|Stroke|Renal Failure
|
April 2009 | Phase 2|Phase 3 |
| NCT05741086 | The First Affiliated Hospital with Nanjing Medical University |
Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis
|
April 15, 2023 | Phase 3 |
| NCT00249249 | Kowa Research Europe |
Primary Hypercholesterolemia|Dyslipidemia
|
October 2005 | Phase 3 |
| NCT04072601 | Copenhagen University Hospital, Hvidovre|University of Copenhagen|Aarhus University Hospital|Rigshospitalet, Denmark |
Liver Cirrhoses
|
November 8, 2019 | Phase 4 |
| NCT01557075 | Yonsei University |
Drug-eluting Stent (DES)
|
July 2010 | Phase 4 |
| NCT02800902 | Government Dental College and Research Institute, Bangalore |
Chronic Periodontitis
|
May 2015 | Phase 2|Phase 3 |
| NCT00127335 | Scripps Health |
Myopathic Conditions
|
August 2005 | Phase 4 |
| NCT01053065 | University of Padova|Biomedical Foundation for Cardiovascular Research of Padova|Pfizer |
Symptomatic Carotid Stenosis|Hypercholesterolemia|Indication for Carotid Endarterectomy
|
Not Applicable | |
| NCT03255044 | Ain Shams University |
Heart Failure
|
June 15, 2017 | Phase 4 |
| NCT03867994 | rabab ahmed mohamed|Cairo University|October 6 University |
Contrast-induced Nephropathy
|
February 1, 2016 | Phase 2 |
| NCT02374047 | Catabasis Pharmaceuticals |
Hypercholesterolemia
|
January 2015 | Phase 1 |
| NCT02350959 | National Health Insurance Service Ilsan Hospital |
Plaque
|
January 2015 | Phase 4 |
| NCT01689623 | Janssen Research & Development, LLC |
Healthy Participants
|
June 2012 | Phase 1 |
| NCT01255852 | Jinling Hospital, China |
CVD
|
January 2011 | Phase 4 |
| NCT02781064 | London School of Hygiene and Tropical Medicine|National Institute for Health Research, United Kingdom |
Cardiovascular Disease
|
September 1, 2016 | Phase 4 |
| NCT02331095 | Ohio State University |
Venous Thromboembolism
|
January 2015 | Early Phase 1 |
| NCT01029522 | Chong Kun Dang Pharmaceutical |
Dyslipidemia
|
August 2008 | Phase 4 |
| NCT03837925 | French Cardiology Society|Fondation Coeur et Recherche|ICAN Nutrition Education and Research|Fédération francaise de cardiologie |
Cardiovascular Diseases
|
June 13, 2019 | Phase 3 |
| NCT00777517 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypercholesterolemia
|
November 2008 | Phase 1 |
| NCT02355704 | Instituto Mexicano del Seguro Social |
Renal Insufficiency
|
January 2012 | Phase 3 |
| NCT02940366 | Seoul National University Hospital|JW Pharmaceutical |
Metabolic Syndrome
|
December 1, 2016 | Phase 4 |
| NCT05946122 | Minia University |
Renal Protection
|
May 30, 2023 | Phase 1 |
| NCT00758004 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypercholesterolemia
|
October 2008 | Phase 1 |
| NCT04922424 | Yale University |
Hypertension|Hyperlipidemias
|
September 30, 2022 | Phase 1 |
| NCT05483894 | Samsung Medical Center |
Hepatitis B|Portal Hypertension
|
August 1, 2022 | Phase 2 |
| NCT05642845 | Pharmtechnology LLC|ClinPharmInvest, LLC |
Bioequivalence
|
November 11, 2022 | Phase 1 |
| NCT00636766 | Aristotle University Of Thessaloniki |
Carotid Atherosclerosis|Stroke|Type 2 Diabetes|Metabolic Syndrome
|
September 2005 | Not Applicable |
| NCT05238012 | Heart Health Research Center|AstraZeneca |
Metabolism Disorder, Lipid|Metabolism Disorder, Glucose
|
July 1, 2022 | Phase 4 |
| NCT03414840 | Yonsei University|Chong Kun Dang Pharmaceutical Corp. |
Coronary Artery Disease|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Coronary Arteriosclerosis
|
April 1, 2018 | |
| NCT04151355 | Ain Shams University|Nasser Institute For Research and Treatment |
Colorectal Cancer
|
October 1, 2019 | Not Applicable |
| NCT02577042 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
Aging-related Inflammation in HIV-infected Patients
|
October 15, 2015 | Phase 4 |
| NCT01442428 | University of Minnesota|Pfizer|Minnesota Medical Foundation |
Immune Reconstitution Inflammatory Syndrome|Immune Reconstitution Syndrome|Tuberculosis|HIV-infection+Aids
|
January 2014 | Phase 2|Phase 3 |
| NCT00683618 | AstraZeneca |
Hypercholesterolemia
|
May 2008 | Phase 3 |
| NCT02024373 | Oriental Neurosurgery Evidence-Based-Study Team |
Chronic Subdural Hematoma
|
December 2013 | Phase 2 |
| NCT02958852 | Lund University Hospital|South Sweden Breast Cancer Group |
Breast Cancer
|
November 2016 | Phase 2 |
| NCT03884452 | Organon and Co |
Familial Hypercholesterolemia
|
May 3, 2000 | Phase 3 |
| NCT00960323 | Mutual Pharmaceutical Company, Inc. |
Healthy
|
February 2009 | Phase 1 |
| NCT02452502 | Second Affiliated Hospital, School of Medicine, Zhejiang University|The First Hospital of Jilin University |
Stroke
|
September 2, 2015 | Not Applicable |
| NCT01770210 | Elpen Pharmaceutical Co. Inc. |
Cardiovascular Disorders
|
February 2013 | |
| NCT05815680 | Innovent Biologics (Suzhou) Co. Ltd. |
Overweight Subjects|Obese Subjects
|
April 6, 2023 | Phase 1 |
| NCT00134550 | Asker & Baerum Hospital|Pfizer |
Foot Ulcer|Diabetes
|
February 2005 | Phase 2 |
| NCT02437084 | Stanford University|Doris Duke Charitable Foundation |
Hyperlipidemia|Insulin Resistance|Type 2 Diabetes
|
May 2015 | Phase 4 |
| NCT00296387 | AstraZeneca |
Acute Coronary Syndrome
|
January 2006 | Phase 3 |
| NCT00355251 | Germans Trias i Pujol Hospital|Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
HIV Infections
|
July 2006 | Phase 4 |
| NCT01555632 | University of Nebraska|National Cancer Institute (NCI) |
Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer
|
March 2012 | Not Applicable |
| NCT01645449 | Dr. Reddy´s Laboratories Limited |
Healthy
|
June 2010 | Phase 1 |
| NCT00889226 | JW Pharmaceutical |
Hypercholesterolemia With Type2DM
|
April 2008 | Phase 4 |
| NCT05289063 | Columbia University|National Heart, Lung, and Blood Institute (NHLBI) |
Obstructive Sleep Apnea of Adult
|
October 3, 2022 | Phase 1 |
| NCT00143741 | University of Chicago |
End-Stage Kidney Disease
|
May 2005 | Phase 1 |
| NCT00145431 | Pfizer |
Hyperlipoproteinemia Type III
|
March 2005 | Phase 3 |
| NCT02197065 | Hospital for Special Surgery, New York|Weill Medical College of Cornell University|Washington University School of Medicine|University of Utah |
Hip Fracture|Myocardial Ischemia|Inflammation
|
September 2014 | Phase 2 |
| NCT00418834 | Organon and Co |
Hypercholesterolemia
|
January 2007 | Phase 3 |
| NCT00654537 | AstraZeneca |
Hypercholesterolemia
|
April 2001 | Phase 3 |
| NCT02518516 | Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR) |
Hypercholesterolemia
|
January 2011 | |
| NCT05072054 | Postgraduate Institute of Medical Education and Research|Indian Council of Medical Research |
Heart Failure With Reduced Ejection Fraction
|
October 16, 2019 | Phase 4 |
| NCT02977065 | Chong Kun Dang Pharmaceutical |
Dyslipidemias
|
March 23, 2017 | Phase 2 |
| NCT01709513 | Regeneron Pharmaceuticals|Sanofi |
Hypercholesterolemia
|
September 30, 2012 | Phase 3 |
| NCT01645410 | Dr. Reddy´s Laboratories Limited |
Healthy
|
March 2009 | Phase 1 |
| NCT00279708 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Sarcoidosis, Pulmonary
|
January 2006 | Phase 2 |
| NCT00132717 | Organon and Co |
Hypercholesterolemia
|
January 1, 2005 | Phase 3 |
| NCT00329069 | University of Ulm|Pfizer |
Coronary Artery Disease|Hypercholesterolemia|Monocyte Function
|
May 2002 | Not Applicable |
| NCT00974740 | Profil Institut für Stoffwechselforschung GmbH|Pfizer |
Type 1 Diabetes
|
March 2004 | Phase 1 |
| NCT00319449 | Organon and Co|PT. Schering-Plough. Tbk Indonesia |
Hypercholesterolemia|Coronary Arteriosclerosis
|
September 2005 | Phase 4 |
| NCT01660191 | University of Kansas Medical Center|Kowa Pharmaceuticals America, Inc.|Eli Lilly and Company |
Hypercholesterolemia
|
December 2011 | Phase 4 |
| NCT00497016 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development |
Hypertension
|
May 2007 | Not Applicable |
| NCT02842359 | Sanofi |
Type 2 Diabetes Mellitus
|
August 23, 2016 | Phase 4 |
| NCT01263938 | University of Pennsylvania|National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Dementia
|
September 2011 | Phase 4 |
| NCT00814255 | NYU Langone Health|University of Michigan|The Cleveland Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Focal Segmental Glomerulosclerosis
|
December 2008 | Phase 2 |
| NCT00211939 | Nabi Biopharmaceuticals |
Calcinosis|Arteriosclerosis|Hyperparathyroidism, Secondary
|
January 2005 | Phase 4 |
| NCT01370590 | Organon and Co |
Hypercholesterolemia
|
September 2011 | Phase 3 |
| NCT04952350 | Mansoura University |
Covid19|SARS-CoV2 Infection|COVID-19 Pneumonia
|
August 14, 2021 | Phase 3 |
| NCT00474240 | Aegerion Pharmaceuticals, Inc. |
Hypercholesterolemia
|
April 2007 | Phase 2 |
| NCT00159718 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Angina
|
July 2001 | Phase 4 |
| NCT02942602 | Yonsei University |
Hyperlipidemia
|
April 3, 2014 | Not Applicable |
| NCT03018444 | University Hospital, Gentofte, Copenhagen |
Diabetes Mellitus, Type 2|Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
October 2016 | Not Applicable |
| NCT03338426 | Boryung Pharmaceutical Co., Ltd |
Essential Hypertension, Dyslipidemia
|
January 15, 2018 | Phase 3 |
| NCT00411190 | GlaxoSmithKline |
Osteoarthritis
|
October 19, 2006 | Phase 1 |
| NCT03009097 | Kamineni Institute of Dental Sciences |
Chronic Periaortitis|Intrabony Periodontal Defect
|
April 2013 | Phase 4 |
| NCT00728910 | University of Pennsylvania|Abbott |
Dyslipidemia
|
June 2008 | Phase 2 |
| NCT00770575 | Takeda |
Cardiovascular Diseases
|
June 2005 | Phase 2 |
| NCT04972396 | Altimmune, Inc. |
NASH - Nonalcoholic Steatohepatitis
|
October 5, 2021 | Phase 1 |
| NCT02133534 | Duke University |
Chronic Kidney Disease|High Cholesterol
|
February 2008 | Phase 4 |
| NCT00639158 | Abbott |
Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipidemia
|
February 2008 | Phase 3 |
| NCT05586750 | Monash University|National Health and Medical Research Council, Australia |
Dementia, Mixed|Dementia, Vascular|Dementia of Alzheimer Type|Cognitive Decline|White Matter Hyperintensity|Aging|Neuro-Degenerative Disease
|
September 19, 2019 | Phase 4 |
| NCT04943783 | Beijing Neurosurgical Institute |
Dissecting Aneurysm of Cerebral Artery|Intramural Hematomas|Inflammation Vascular
|
July 1, 2021 | Not Applicable |
| NCT02791958 | Ferrer Internacional S.A. |
Hypertension
|
March 2016 | Phase 2 |
| NCT04607447 | Huashan Hospital |
Chronic Subdural Hematoma
|
August 4, 2020 | Not Applicable |
| NCT02397590 | Boryung Pharmaceutical Co., Ltd|Seoul National University Hospital |
Hypertension
|
March 2015 | Phase 1 |
| NCT01674686 | Samsung Medical Center |
Variant Angina
|
August 1, 2012 | Phase 4 |
| NCT00754507 | Daiichi Sankyo, Inc. |
Hypercholesterolemia
|
November 2002 | Phase 4 |
| NCT04149483 | Beijing Neurosurgical Institute |
Intracranial Aneurysm|Inflammation Vascular
|
November 7, 2019 | Phase 2 |
| NCT00615823 | Chinese Academy of Medical Sciences, Fuwai Hospital|National Grant from The Ministry of Science and Technology|Capital Development Scientific Fund |
Hypertension, Pulmonary
|
February 2007 | Phase 2 |
| NCT02790528 | Seung-Jung Park|CardioVascular Research Foundation, Korea|Asan Medical Center |
Angina Pectoris, Variant|Statins, HMG-CoA
|
July 2017 | Phase 4 |
| NCT00585611 | University of Wisconsin, Madison |
Diastolic Heart Failure
|
December 2005 | Not Applicable |
| NCT02587416 | NeuroBo Pharmaceuticals Inc. |
Hypercholesteremia
|
November 2002 | Phase 1 |
| NCT05792540 | Tanta University|Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University|Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University|Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University |
Depressive Disorder
|
June 6, 2023 | Phase 2 |
| NCT02590653 | Penza State University |
Myocardial Infarction
|
October 2014 | Phase 4 |
| NCT00979940 | Indiana University School of Medicine|National Center for Research Resources (NCRR)|Indiana University |
Coronary Artery Disease
|
November 2008 | Not Applicable |
| NCT01646307 | Beijing Anzhen Hospital |
Focus of Study
|
January 2012 | Phase 4 |
| NCT00504829 | Veloxis Pharmaceuticals |
Dyslipidemia
|
July 2007 | Phase 2 |
| NCT02254824 | Chinese Academy of Medical Sciences, Fuwai Hospital|Peking University First Hospital|Peking Union Medical College Hospital|Beijing Hospital of Traditional Chinese Medicine |
Hypertension
|
October 2013 | Phase 4 |
| NCT01527045 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) |
Aggressive Non-Hodgkin Lymphoma|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Chronic Lymphocytic Leukemia|Loss of Chromosome 17p|Myelodysplastic+Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Aggressive Adult Non-Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia
|
September 25, 2012 | Phase 2 |
| NCT00973986 | Liuhuaqiao Hospital|Guangdong Province, Department of Science and Technology |
Coronary Heart Disease
|
June 2009 | Phase 1 |
| NCT01059864 | Pfizer |
Rheumatoid Arthritis
|
February 2010 | Phase 2 |
| NCT05790499 | Wuhan Union Hospital, China |
Cholesterol Variability|Trained Immunity
|
March 20, 2023 | Not Applicable |
| NCT02579356 | Samil Pharmaceutical Co., Ltd. |
Diseases of the Circulatory System|Essential Hypertension
|
May 2014 | Phase 1 |
| NCT00864643 | Takeda |
Hypercholesterolemia
|
September 2004 | Phase 2 |
| NCT00414531 | University of Oslo School of Pharmacy |
Myotoxicity of Atorvastatin Treatment
|
May 2005 | Phase 4 |
| NCT01516879 | Amgen |
Hypercholesterolemia
|
January 5, 2012 | Phase 3 |
| NCT00134238 | Pfizer |
Mixed Hyperlipidemia
|
November 2003 | Phase 3 |
| NCT02458755 | Samsung Medical Center|Don-A Pharmaceutical, Seoul, South Korea |
Stroke|Intracranial Atherosclerosis
|
February 2012 | Phase 4 |
| NCT02171039 | Boehringer Ingelheim |
Healthy
|
June 2006 | Phase 1 |
| NCT01081548 | Yonsei University |
Hypercholesterolemia
|
August 2008 | Phase 4 |
| NCT02219191 | Chengdu PLA General Hospital |
Rheumatoid Arthritis
|
August 2014 | Not Applicable |
| NCT03966859 | University of Oxford|Wellcome Trust |
Healthy
|
June 19, 2019 | Not Applicable |
| NCT01527097 | shmuel fuchs|Rabin Medical Center |
Psoriasis
|
August 2012 | Phase 3 |
| NCT00491751 | Boston University |
Peripheral Arterial Disease
|
May 2004 | Phase 1 |
| NCT00529191 | Children´s Hospital of Philadelphia|FDA Office of Orphan Products Development|Medical University of South Carolina |
Type 1 Diabetes
|
July 2007 | Phase 2 |
| NCT05488067 | Children´s Hospital of Fudan University |
Alagille Syndrome|Atorvastatin|Xanthoma
|
March 22, 2022 | Phase 4 |
| NCT00654173 | AstraZeneca |
Hypercholesterolemia
|
June 2002 | Phase 3 |
| NCT00174330 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypertension|Hyperlipidemia
|
May 2005 | Phase 4 |
| NCT04974814 | Beni-Suef University |
ST Elevation Myocardial Infarction
|
May 26, 2021 | Not Applicable |
| NCT00871351 | Organon and Co |
Primary Hypercholesterolemia
|
February 1, 2009 | Phase 4 |
| NCT01645384 | Dr. Reddy´s Laboratories Limited |
Healthy
|
May 2009 | Phase 1 |
| NCT03784703 | Damanhour University|Tanta University |
Dyslipidemia Associated With Type II Diabetes Mellitus
|
January 1, 2018 | Phase 4 |
| NCT04388501 | Janssen Pharmaceutica N.V., Belgium |
Healthy
|
June 7, 2021 | Phase 1 |
| NCT01278459 | University of Oxford |
Pre-Eclampsia
|
October 2011 | Phase 3 |
| NCT02674204 | Cedars-Sinai Medical Center|California Breast Cancer Research Program |
Breast Cancer|Heart Disease|Cardiotoxicity|Myocardial Dysfunction
|
May 5, 2016 | Phase 2 |
| NCT02225834 | University of Palermo |
Ischemic Stroke
|
November 2011 | Phase 4 |
| NCT03066466 | Loyola University |
Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome
|
December 10, 2019 | Phase 3 |
| NCT05747768 | Peking University Third Hospital |
Chronic Kidney Disease
|
July 15, 2022 | Phase 4 |
| NCT01842230 | Chong Kun Dang Pharmaceutical |
Essential Hypertension|Hyperlipidemia
|
April 2013 | Phase 1 |
| NCT00092716 | Organon and Co |
Hypercholesterolemia
|
May 2002 | Phase 3 |
| NCT00166504 | Organon and Co |
Hypercholesterolemia
|
October 2005 | Phase 4 |
| NCT04575857 | University of Washington|Manmohan Cardiothoracic Vascular and Transplant Center|National Heart, Lung, and Blood Institute (NHLBI) |
Rheumatic Heart Disease|Valvular Disease
|
February 8, 2022 | |
| NCT00296374 | AstraZeneca |
Diabetes Mellitus
|
February 2006 | Phase 2 |
| NCT00620204 | Samsung Medical Center |
Angina Pectoris, Variant
|
January 2008 | Phase 4 |
| NCT03079115 | Beijing Hospital |
Carotid Artery Stenosis
|
August 21, 2017 | Phase 4 |
| NCT00653744 | AstraZeneca |
Hypercholesterolemia|Dyslipidaemia
|
March 2002 | Phase 3 |
| NCT03308578 | Mayo Clinic|National Heart, Lung, and Blood Institute (NHLBI) |
Sleep Apnea, Obstructive
|
January 8, 2018 | Phase 1|Phase 2 |
| NCT00653965 | AstraZeneca |
Hypercholesterolemia|Dyslipidaemia
|
May 2003 | Phase 3 |
| NCT00289900 | Merck Sharp & Dohme LLC |
Mixed Hyperlipidemia
|
January 24, 2006 | Phase 3 |
| NCT00479388 | Merck Sharp & Dohme LLC |
Primary Hypercholesterolemia|Mixed Dyslipidemia
|
July 2007 | Phase 3 |
| NCT01304641 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Cardiovascular|Dyslipidemia
|
November 2009 | |
| NCT00678184 | Regional Hospital Holstebro |
Healthy Subjects
|
January 2007 | Phase 4 |
| NCT02432040 | Philippine Dermatological Society |
Psoriasis
|
February 2013 | Phase 2 |
| NCT00395486 | AstraZeneca |
Metabolic Syndrome X
|
September 2006 | Phase 4 |
| NCT00579098 | Mayo Clinic|Pfizer |
Atrial Fibrillation|Arrhythmia|Inflammation|Endothelial Dysfunction
|
December 2007 | Phase 4 |
| NCT00977288 | Merck Sharp & Dohme LLC |
Dyslipidemia
|
September 2009 | Phase 2 |
| NCT04325009 | Dong-A ST Co., Ltd. |
Healthy
|
March 30, 2020 | Phase 1 |
| NCT03110848 | University of Pisa |
Thyroid Associated Ophthalmopathy|Hypercholesterolemia
|
June 1, 2020 | Phase 2 |
| NCT00816244 | Lund University Hospital |
Breast Cancer|Postmenopausal
|
January 2009 | Phase 2 |
| NCT05796973 | Tampere University Hospital|Tampere University|Aalto University|University of Helsinki|University of Turku |
Prostate Cancer|Breast Cancer|Kidney Cancer|Ovarian Cancer|Metastatic Breast Cancer|Metastatic Kidney Cancer|Metastatic Renal Cell Carcinoma|Metastatic Renal Cancer|Metastatic Prostate Cancer|Metastatic Prostate Adenocarcinoma|Metastatic Ovarian Cancer|Metastatic Ovary Cancer
|
March 31, 2023 | Phase 3 |
| NCT05567068 | Tanta University |
Inflammatory Bowel Diseases
|
February 1, 2023 | Phase 2 |
| NCT01970215 | Xention Ltd |
Dyslipidemia
|
August 2013 | Phase 2 |
| NCT00640549 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hyperlipidemia|Diabetes Mellitus, Type 2|Non-Insulin Dependent Diabetes Mellitus
|
March 2003 | Phase 4 |
| NCT03195153 | University of Roma La Sapienza |
Diabetes Mellitus Type 2 Platelets Reactivity Statin
|
March 28, 2017 | Phase 4 |
| NCT02614352 | Ahn-Gook Pharmaceuticals Co.,Ltd |
Healthy Male Subjects
|
Phase 1 | |
| NCT04221321 | HK inno.N Corporation |
Healthy
|
January 7, 2020 | Phase 1 |
| NCT00317967 | University of Calgary|Heart and Stroke Foundation of Canada |
Hypertrophic Cardiomyopathy
|
April 2007 | Phase 3 |
| NCT01259284 | M.D. Anderson Cancer Center |
Advanced Cancers
|
January 2011 | Phase 2|Phase 3 |
| NCT00610870 | Samsung Medical Center |
Angioplasty, Transluminal, Percutaneous Coronary
|
July 2007 | Not Applicable |
| NCT01299194 | University of Edinburgh|NHS Lothian |
BRONCHIECTASIS
|
November 2010 | Phase 4 |
| NCT03358017 | Mario Negri Institute for Pharmacological Research|Associazione Italiana per la Ricerca sul Cancro |
Triple Negative Breast Cancer
|
March 5, 2018 | Phase 2 |
| NCT01856374 | Yonsei University |
Multi-vessel Diseases, Angina
|
August 2011 | Phase 4 |
| NCT01332747 | Jamia Hamdard University |
Hyperlipidemia
|
May 2010 | Phase 2 |
| NCT04215237 | First Affiliated Hospital Xi´an Jiaotong University |
Atherosclerotic Cardiovascular Disease
|
November 13, 2017 | Not Applicable |
| NCT00664846 | Peking Union Medical College Hospital |
Stroke
|
April 2008 | Not Applicable |
| NCT00728988 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Acute Coronary Syndrome
|
September 2008 | Phase 4 |
| NCT01491958 | Ohio State University Comprehensive Cancer Center |
Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome
|
December 10, 2011 | Phase 2 |
| NCT01334671 | General Hospital of Chinese Armed Police Forces |
ST-elevation Myocardial Infarction|(STEMI)
|
February 2011 | Phase 3 |
| NCT01279590 | Furiex Pharmaceuticals, Inc |
Myalgia|Hypercholesterolemia|Hyperlipidemia
|
March 2011 | Phase 2 |
| NCT00159835 | Pfizer |
Cardiovascular Diseases
|
February 1999 | Phase 4 |
| NCT01499758 | Ranbaxy Laboratories Limited|Ranbaxy Inc. |
Healthy
|
October 2009 | Phase 1 |
| NCT03415178 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolaemia
|
March 29, 2018 | Phase 3 |
| NCT03604471 | Université Catholique de Louvain|Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Hypercholesterolemia
|
August 8, 2017 | Phase 4 |
| NCT02081638 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Human Immunodeficiency Virus
|
April 18, 2014 | Phase 2 |
| NCT00375518 | Memorial Sloan Kettering Cancer Center |
Thoracic Surgery
|
July 2006 | Not Applicable |
| NCT02378441 | HK inno.N Corporation |
Healthy
|
February 2015 | Phase 1 |
| NCT00164086 | Bayside Health |
Myeloma
|
Phase 1 | |
| NCT01544309 | Listen Trial Group |
Hypercholesterolemia With Concomitant Type 2 Diabetes
|
March 2012 | Not Applicable |
| NCT01288469 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolemia
|
January 2011 | Phase 2 |
| NCT03625089 | Chinese University of Hong Kong |
Arthritis, Rheumatoid|Arthritis, Psoriatic
|
September 1, 2018 | Not Applicable |
| NCT00522158 | Baskent University |
Type 2 Diabetes Mellitus|Cardiovascular Disease|LDL Cholesterol|Cognition
|
Phase 4 | |
| NCT00654095 | Organon and Co |
Hypercholesterolemia
|
December 1, 2007 | Phase 3 |
| NCT00115830 | Brigham and Women´s Hospital |
Atherosclerosis
|
December 2004 | Phase 3 |
| NCT03311841 | Merck Sharp & Dohme LLC |
Renal Insufficiency
|
March 1, 2018 | Phase 1 |
| NCT00917579 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Hypercholesterolemia
|
July 2008 | Phase 4 |
| NCT00380939 | Pfizer |
Coronary Arteriosclerosis
|
April 1999 | Phase 4 |
| NCT00650689 | Organon and Co|Merck Sharp & Dohme LLC |
Hypercholesterolemia|Atherosclerosis|Coronary Artery Disease
|
May 2003 | Phase 3 |
| NCT00435045 | GlaxoSmithKline |
Hypertriglyceridemia
|
February 2007 | Phase 3 |
| NCT01222182 | Mayo Clinic |
Hypercholesterolemia
|
September 2009 | |
| NCT00627575 | GlaxoSmithKline |
Epilepsy
|
February 4, 2008 | Phase 1 |
| NCT02035215 | Kuhnil Pharmaceutical Co., Ltd. |
Hyperlipidemia, Familial Combined
|
January 2014 | Phase 3 |
| NCT00172419 | National Taiwan University Hospital|National Science Council, Taiwan|Pfizer |
Hyperlipidemia
|
March 2007 | Not Applicable |
| NCT00653796 | Organon and Co|Merck Sharp & Dohme LLC |
Hypercholesterolemia|Atherosclerosis
|
September 1, 2003 | Phase 4 |
| NCT02411903 | The Third Affiliated Hospital of Guangzhou Medical University |
Cerebral Infarction|Clopidogrel,Poor Metabolism of (Disorder)
|
March 2015 | Phase 4 |
| NCT02029573 | King Fahad Medical City |
Glioblastoma Multiforme
|
January 1, 2014 | Phase 2 |
| NCT00300430 | Abbott |
Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia
|
September 2006 | Phase 3 |
| NCT00163150 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Cerebrovascular Accident|Hypercholesterolemia
|
June 2003 | Phase 4 |
| NCT02947620 | Daewoong Pharmaceutical Co. LTD. |
Type II Diabetes|Dyslipidemia
|
August 2015 | Phase 3 |
| NCT00520585 | Masaryk University |
Heterogeneity of Cardiomyocytes Repolarisation|Autonomic Changes of Cardiomyocytes Repolarisation
|
August 2007 | Not Applicable |
| NCT02715726 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolemia
|
July 27, 2016 | Phase 3 |
| NCT00700037 | Wakayama Medical University |
Acute Coronary Syndrome|Atherosclerosis|Dyslipidemia
|
August 2009 | Phase 4 |
| NCT02476006 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolemia
|
June 23, 2015 | Phase 3 |
| NCT00166530 | Organon and Co |
Atherosclerosis
|
November 2005 | Phase 4 |
| NCT01925937 | Isfahan University of Medical Sciences |
Congestive Heart Failure
|
June 2013 | Not Applicable |
| NCT03510884 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolaemia
|
May 31, 2018 | Phase 3 |
| NCT00090168 | Organon and Co |
Hypercholesterolemia|Atherosclerotic Disease|Coronary Disease
|
January 27, 2004 | Phase 3 |
| NCT00768638 | Laval University |
Chronic Kidney Disease
|
October 2008 | Phase 4 |
| NCT02370784 | Robyn T. Domsic, MD, MPH|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|University of Pittsburgh |
Scleroderma
|
February 2015 | Phase 2 |
| NCT00637481 | National Cancer Institute (NCI) |
Atypical Ductal Breast Hyperplasia|Breast Cancer|Ductal Breast Carcinoma in Situ|Lobular Breast Carcinoma in Situ
|
March 2008 | Phase 1 |
| NCT04047940 | Eli Lilly and Company |
Healthy
|
November 29, 2019 | Phase 1 |
| NCT04466241 | ANRS, Emerging Infectious Diseases|University of Bordeaux|PACCI Program |
COVID-19|COVID-19 Drug Treatment|Severe Acute Respiratory Syndrome Coronavirus 2
|
November 27, 2020 | Phase 2|Phase 3 |
| NCT02205775 | G. d´Annunzio University|Working Group Aterosclerosi, Trombosi e Biologia Vascolare |
Stable Coronary Artery Disease Undergoing PCI
|
May 2010 | Phase 3 |
| NCT03709355 | Viriom |
HIV-1-infection
|
November 14, 2018 | Phase 1 |
| NCT00664469 | Sunnybrook Health Sciences Centre|Merck Frosst Canada Ltd.|Schering-Plough |
Hypercholesterolemia
|
August 2007 | Phase 3 |
| NCT03611010 | Cumberland Pharmaceuticals |
Hypercholesterolemia|Dyslipidemias
|
August 7, 2018 | Phase 2 |
| NCT03024684 | Chiayi Christian Hospital|E-DA Hospital|National Taiwan University Hospital|Taichung Veterans General Hospital|Mackay Memorial Hospital|Tainan Municipal Hospital|National Cheng-Kung University Hospital|Chi Mei Medical Hospital |
HepatoCellular Carcinoma
|
January 3, 2017 | Phase 4 |
| NCT04270370 | Eli Lilly and Company |
Healthy
|
March 16, 2020 | Phase 1 |
| NCT02641899 | Intarcia Therapeutics |
Healthy
|
December 2015 | Phase 1 |
| NCT01567774 | University of Roma La Sapienza |
Coronary Artery Disease
|
April 2012 | Phase 4 |
| NCT01785615 | University of Rochester|Pfizer |
Metabolic Syndrome
|
November 2004 | Phase 1|Phase 2 |
| NCT00130481 | University of Florida |
Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus
|
April 2005 | Not Applicable |
| NCT00356473 | University of California, Los Angeles |
Rheumatoid Arthritis
|
March 2003 | Phase 4 |
| NCT01370603 | Organon and Co |
Hypercholesterolemia
|
September 2011 | Phase 3 |
| NCT02584504 | Sanofi|Regeneron Pharmaceuticals |
Hypercholesterolemia
|
November 30, 2015 | Phase 3 |
| NCT01692717 | Azidus Brasil |
Healthy Subjects
|
February 28, 2013 | Phase 1 |
| NCT01112670 | University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Healthy
|
November 2009 | Phase 4 |
| NCT01544751 | Prof Antonino Belfiore|University Magna Graecia |
Nonalcoholic Fatty Liver Disease (NAFLD)
|
September 2011 | Not Applicable |
| NCT00147602 | Pfizer |
Cardiovascular Disease
|
November 1998 | Phase 4 |
| NCT00442897 | Organon and Co |
Hypercholesterolemia
|
September 2006 | Phase 4 |
| NCT02029534 | Creighton University |
Cardiothoracic Surgery|Post-operative Atrial Fibrillation
|
August 2013 | Phase 4 |
| NCT02155530 | Yonsei University |
Coronary Artery Disease
|
June 2014 | Not Applicable |
| NCT00703261 | Merck Sharp & Dohme LLC |
Atherosclerotic Vascular Disease
|
August 2008 | Phase 1 |
| NCT02227784 | Eli Lilly and Company |
Hyperlipidemia
|
October 2014 | Phase 3 |
| NCT02588235 | Xijing Hospital |
Coronary Artery Disease
|
October 2015 | Phase 4 |
| NCT01605344 | UNC Lineberger Comprehensive Cancer Center |
Advanced Adenocarcinoma of the Colon or Rectum
|
April 2012 | Phase 1 |
| NCT05327595 | Eli Lilly and Company |
Diabetes Mellitus, Type 2
|
May 9, 2022 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL ( 89.50 mM ; Need ultrasonic)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7901 mL | 8.9503 mL | 17.9006 mL |
| 5 mM | 0.3580 mL | 1.7901 mL | 3.5801 mL |
| 10 mM | 0.1790 mL | 0.8950 mL | 1.7901 mL |
*
Please refer to the solubility information to select the appropriate solvent.
In Vivo:
-
1.
-
2.
*
All of the co-solvents are available by MedChemExpress (MCE).
References
- [1] Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22.
- [2] Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61.
- [3] Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82.
- [4] Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72.
- [5] Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821.
- [6] Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42(5):409-415.
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.